

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023062
Article Type:	Research
Date Submitted by the Author:	25-Mar-2018
Complete List of Authors:	Tang, Chao-Hsiun ; Taipei Medical University, School of Health Care Administration, College of Management Chen, Hsi-Hsien; Taipei Medical University Hospital, Division of Nephrology, Department of Internal Medicine, Wu, Ming-Ju; Taichung Veterans General Hospital, Division of Nephrology, Department of Internal Medicine Hsu, Bang-Gee ; Buddhist Tzu Chi General Hospital, Division of Nephrology, Department of Internal Medicine Tsai, Jer-Chia ; Kaohsiung Medical University Chung Ho Memorial Hospital, Department of Internal Medicine Kuo, Chi-Cheng; Taipei Medical University, School of Health Care Administration, College of Management Lin, Ship-Pi; Lenity Clinic, Lenity Clinic Chen, Tso-Hsiao ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, SUE, YUH-MOU; School of Medicine, College of Medicine, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine,
Keywords:	cost, haemodialysis, out-of-pocket cost, peritoneal dialysis, productivity loss

SCHOLARONE™
Manuscripts

1
2
3 **Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis**
4 **from a patient interview survey in Taiwan**

5 **Running title:** Costs of HD and PD in Taiwan

6
7
8 **Authors:**

9
10 Chao-Hsiun Tang, PhD¹, Hsi-Hsien Chen, MD, PhD², Ming-Ju Wu, MD, PhD³, Bang-Gee Hsu,
11 MD, PhD⁴, Jer-Chia Tsai, MD⁵, Chi-Cheng Kuo, MBA¹, Shih-Pi Lin, MD⁶, Tso-Hsiao Chen,
12 MD, PhD⁷, Yuh-Mou Sue, MD⁷

13
14
15 **Affiliations:**

16
17 ¹School of Health Care Administration, College of Management, Taipei Medical University,
18 Taipei, Taiwan

19
20 ²Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
21 Medicine and Division of Nephrology, Department of Internal Medicine, Taipei Medical
22 University Hospital, Taipei Medical University, Taipei, Taiwan

23
24 ³Division of Nephrology, Department of Internal Medicine, Taichung Veterans General
25 Hospital, Taichung, Taiwan

26
27 ⁴Division of Nephrology, Department of Internal Medicine, Buddhist Tzu Chi General
28 Hospital and School of Medicine, Tzu Chi University, Hualien, Taiwan

29
30 ⁵Department of Internal Medicine, Kaohsiung Medical University Hospital and Faculty of
31 Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

32
33 ⁶Lenity Clinic, Kaohsiung, Taiwan

34
35 ⁷Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
36 Medicine and Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital,
37 Taipei Medical University, Taipei, Taiwan

38
39
40
41
42
43
44 **Correspondence:** Yuh-Mou Sue, MD, Division of Nephrology, Department of Internal
45 Medicine, Wan Fang Hospital, Taipei Medical University, 5th Floor, 111 Xing Long Road,
46 Section 3, Taipei 116, Taiwan

47
48
49 E-mail: sueym@tmu.edu.tw; Tel: 886-2-29307930-8103; Fax: 886-2-29302448

ABSTRACT

Objectives: The total medical (economic) costs of haemodialysis (HD) and peritoneal dialysis (PD), including direct medical costs, out-of-pocket (OOP) costs, and productivity losses, have become an important issue. This study aims to compare the direct non-medical costs and indirect medical costs of both modalities in Taiwan.

Design and Setting: This multicentre study included cross-sectional interviews of patients over 20 years old and articulate, who had been continuously receiving long-term HD or PD for more than three months between April 2015 and March 2016. Mann-Whitney U test, Wilcoxon rank sum test, and 1,000 bootstrap procedures with replacement were used for analysis.

Outcome measures: Differences in OOP costs and productivity losses.

Results: There were 308 HD and 246 PD patients available for analysis. HD patients had significantly higher monthly OOP costs than PD patients after bootstrap procedures (NTD 5,912 vs. NTD 5,225, $p < 0.001$; NTD, New Taiwan Dollars; 1 US Dollar = 30 NTD). Compared with PD patients, HD patients had higher monthly productivity losses after bootstrap procedures (NTD 14,150 vs. NTD 11,611, $p < 0.001$), resulting from more time spent seeking outpatient care (HD, 70.4 hours vs. PD, 4.4 hours, $p < 0.001$) and time spent by family caregivers for outpatient care (HD, 66.1 hours vs. PD, 6.1 hours, $p < 0.001$). The total costs per patient-month of HD and PD modalities, including OOP costs and productivity losses after adjusted for unemployment rate (3.82%) were NTD 19,522 and NTD 16,392, respectively.

Conclusions: The HD modality has higher OOP costs and productivity losses than the PD modality in Taiwan.

Keywords: cost, haemodialysis; out-of-pocket cost; peritoneal dialysis; productivity loss

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This multicentre study included cross-sectional interviews of long-term HD and PD patients.
- Previous study seldom assessed the information about out-of-pocket payments and productivity losses collected from patient undergoing HD and PD.
- The difference in the proportion of age groups in HD and PD patients are the major drawback of this study.
- The sample size could not represent the general population of HD and PD patients in Taiwan because the sampled patients were also not randomised

INTRODUCTION

Since March 1995, when Taiwan began implementing the National Health Insurance (NHI) system, the per capita healthcare expenditure has increased annually, especially in the care of 'end-stage renal disease' (ESRD) patients. Taiwan has the highest incidence and prevalence rates of ESRD in the world.¹⁻³ By 2017, the cost of dialysis (New Taiwan Dollar, NTD 36.9 billion; 1 US dollar = 30 NTDs in Dec. 2017) accounted for a staggering 5.73% of the total annual NHI expenditure (NTD 644.1 billion).³ Haemodialysis (HD) and peritoneal dialysis (PD) are the two major renal replacement modalities in Taiwan with a similar all-cause mortality rate.⁴⁻⁷ Several studies have provided clear evidence that HD has the higher direct medical costs among the two modalities.⁸⁻¹⁴ NHI administrators implemented several strategies besides applying a blanket budget cap on dialysis expenditure to contain the total costs of dialysis and incentivize the use of PD modality. These efforts included increasing the reimbursements for PD and extending the NHI payment scheme covering the automated PD machine costs. As the proportion of PD usage increases, its prevalence in Taiwan has been gradually increasing, from 6.5% in 2003 to 8.5% in 2007, and up to 9.2% in 2014, similar to the average level within the developed countries.¹⁵⁻¹⁸

ESRD prevalence is increasing with the rise in the number of aging and diabetic nephropathy patients. The total (economic) costs of HD and PD modalities, including direct medical costs, direct non-medical costs, and productivity losses, have become an important issue.¹⁹ Direct medical costs incurred for medical services, such as dialysis costs, physician and nurses' services, diagnostic tests, and hospitalization costs, are the most common type cited in the nephrologic literature. From a payer's perspective (e.g., national insurance organizations), these costs are the most important. However, from a patient's as well as societal perspectives, out-of-pocket (OOP) costs and productivity losses are nominal and meaningful. OOP costs and productivity losses have not been assessed comprehensively in

1
2
3 ESRD patients for two reasons: the methods for collecting these data for the ESRD patients
4 are not well established, and retrospective data collection is difficult. Only two studies have
5 reported that PD had less OOP costs and productivity losses than HD in Brazil and Singapore,
6 but detailed data were not stated.^{12 20} These studies highlighted a significant economic burden
7 due to dialysis and a higher direct healthcare costs associated with the use of HD modality;
8 however, little information is available about OOP costs, including expenses on caregivers or
9 transportation, as well as productivity losses, including job loss, worker replacement, and
10 reduced productivity from patients and family. According to the 2016 Annual Report on
11 Kidney Disease in Taiwan, HD patients had higher NHI expenses (NTD 70,000 per
12 patient-month) than PD patients (NTD 51,000 per patient-month), owing to higher cost of
13 outpatient care (HD, NTD 56,000 per patient-month; PD, NTD 43,000 per patient-month)
14 and inpatient care (HD, NTD 13,400 per patient-month; PD, NTD 8,200 per patient-month).¹⁵
15
16 However, the extent to which OOP costs and productivity losses contribute to the overall
17 economic burden of HD and PD are yet to be explored in Taiwan. We, therefore, conducted
18 this study from a patient's and societal perspectives, using face-to-face interviews to compare
19 OOP costs and productivity losses between HD and PD patients in Taiwan.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **METHODS**

40 **Study Design**

41
42 Ours was a multicentre study using cross-sectional interviews with patients over 20
43 years old, carried out at the nephrology outpatient clinics of five hospitals and five dialysis
44 clinics located in northern, central, southern, and eastern Taiwan between April 2015 and
45 March 2016. The Joint Institutional Review Board of Taipei Medical University approved
46 this study (No. 201503057). All participants provided informed consent to participate in this
47 study. All aspects of the study were performed in accordance with relevant guidelines and
48 regulations. No patients were asked for input in the creation of this article.
49
50
51
52
53
54
55
56
57
58
59
60

Sampling

Articulate ESRD patients who were receiving long-term HD or PD continuously for more than three months were chosen. Those aged less than 20 years or unable to communicate were excluded. Patients were recruited and enrolled using a 1:1 male-to-female enrolment design. A total of 581 ESRD patients were screened at the contributing sites, of whom 554 were eligible and enrolled. In total, there were 308 HD patients (156 men, 152 women) and 246 PD patients (124 men, 122 women; 117 automated PD, 129 continuous ambulatory PD) available for analysis.

The patient interviews were performed face by face by well-trained nurses from the site or graduate students from the Taipei Medical University. All interviewers had attended prior interviewer training. The patients' baseline characteristics were collected from their medical chart and own response. The patient details collected include sociodemographics, comorbidities, cause of ESRD, and dialysis data (Table 1 and 2). We examine the differences in OOP costs and productivity losses between HD and PD patients. OOP costs included all expenses related to ESRD paid by the patients/family and not reimbursed by the NHI, such as expenses for medicines, medical materials and devices, herbal and alternative medicines, nutritional supplements, transportation costs, and caregiver costs. By using the 'human capital approach',²¹ productivity losses were valued and measured by multiplying the loss of time in hours or days with average hourly/daily wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan (see supplementary Table S1). There were two sources of time loss being evaluated: patients' and caregivers' time spent in seeking care and time spent in operating the dialysis apparatus at home.

Statistical Analysis

The analyses began with a baseline comparison of patients receiving either HD or PD therapy. Frequencies for categorical variables and means with standard deviations or medians

1
2
3 with interquartile ranges for continuous variables were calculated. Statistical differences
4 between the HD and PD patients were determined with Chi-square (χ^2) tests, Mann-Whitney
5 U test and Wilcoxon rank sum test as appropriate to analyse the patient interview survey data.
6
7 Finally, as patient characteristics and costs may differ outside clinical settings and in different
8 conditions, a bootstrap analysis was further performed on OOP costs and productivity losses,
9 by applying 1,000 bootstrap procedures of HD and PD patients with replacement, stratified
10 by age groups. The difference between the groups was significant for the two-sided p -value
11 <0.05 . All the analyses in this study were carried out using the SAS 9.3 software (SAS
12 Institute Inc., Cary, NC, USA).
13
14
15
16
17
18
19
20
21

22 **Sensitivity Analysis**

23
24 Moreover, the HD and PD patients are a group of patients with a debilitating illness and
25 may receive lower wage rates than the general population resulting in lower productivity
26 losses. To assess the impact of productivity losses on the sum of OOP costs and productivity
27 losses, we adjusted the productivity losses for the mean Taiwan unemployment rate (3.82%)
28 during the interview period (between April 2015 and March 2016) and then set the
29 productivity losses with a 20%, 30%, or 40% decrement of wages as different scenarios to
30 calculate the total amount of these two costs.²²
31
32
33
34
35
36
37
38
39
40

41 **RESULTS**

42
43 A total of 308 HD patients and 246 PD patients were interviewed in the multicentre
44 cross-sectional study. Patient baseline characteristics are shown in Table 1. HD patients were
45 older as more patients were over 70 years old. Diabetes and ischemic heart disease
46 prevalence was higher and hypertension was lower in HD patients. Hypertension and lupus
47 nephritis had a discernibly different causation of ESRD between the HD and PD patients.
48
49 Marital status, education, and income were not statistically different between the groups. The
50 dialysis-related baseline data are reported in Table 2, where the maximum differences were
51
52
53
54
55
56
57
58
59
60

1
2
3 found to be the duration of dialysis, haemoglobin, serum albumin, and potassium.

4
5 Table 3 shows the results of the per patient-month OOP costs. There were discernible
6
7 differences between the HD and PD patients in the OOP costs (NTD 5,922 vs. NTD 5,237, p
8
9 <0.01). The HD patients had significantly lower copayment for outpatient visits, medicine not
10
11 covered by NHI, and medical equipment, but higher copayment for hospitalizations and
12
13 transportation than the PD patients. Chinese medication, traditional medicine, and nutritional
14
15 supplements showed no discernible differences between groups. Another main source of the
16
17 differences between the HD and PD patients were the transportation costs, owing to more
18
19 frequent transportation in the former group. However, the results of the mean OOP costs were
20
21 not consistent in each age group. PD patients had significantly higher OOP costs than the
22
23 corresponding HD patients in the age groups of 50–59 years old and over 70 years old.
24
25

26
27 Results of the per patient-month productivity losses are reported in Table 4. Compared
28
29 with the PD patients, the HD patients had higher monthly productivity losses (NTD 14,147 vs.
30
31 NTD 11,604, $p <0.01$), resulting from more time spent seeking outpatient care (HD, $70.4 \pm$
32
33 6.9 hours vs. PD, 4.4 ± 2.5 hours, $p <0.001$) and time spent by family caregivers for
34
35 outpatient care (HD, 66.1 ± 51.5 hours vs. PD, 6.1 ± 4.1 hours, $p <0.001$). However, only
36
37 10.4% and 31.3% of HD and PD patients, respectively, had family caregivers who
38
39 accompanied them for outpatient care. The productivity losses resulting from time spent
40
41 operating the dialysis apparatus (49.9 ± 27.8 hours) were only seen in PD patients but not HD
42
43 patients. After the 1,000 bootstrap procedures, the results of the mean productivity losses
44
45 remained unchanged in each age group. HD patients had significantly lower productivity
46
47 losses in the age group over 70 years old because no productivity losses were included
48
49 beyond the age of 70 years.
50
51

52
53 Table 5 reports the total costs per patient-month, including OOP costs and productivity
54
55 losses. The productivity losses were further adjusted for mean Taiwan unemployment rate
56
57
58
59

1
2
3 (3.82%) during the interview survey periods. Models 3–6 show the total costs including OOP
4 costs and productivity losses adjusted for unemployment rate with a 20%, 30%, or 40%
5 decrement of wages as different scenarios. After considering the productivity losses under
6 various scenarios, the differences of total costs between the HD and PD patients slightly
7 decreased in Models 4–6. After stratified by age groups, the total costs per patient-month of
8 HD patients were higher than those of PD patients except in the age group older than 70 years
9 old.
10
11
12
13
14
15
16
17

18 Incorporating the NHI-financed medical costs of HD and PD reported in the 2016
19 Annual Report on Kidney Disease in Taiwan into the findings in this study¹⁵, Figure 1 shows
20 the per patient-month total costs are NTD 89,522 for HD and NTD 67,392 for PD, to which
21 OOP costs contributed 6.6% and 7.8%, and productivity losses 15.2% and 16.6%,
22 respectively. For the NTD 22,130 per-patient-month difference in the costs of HD and PD,
23 OOP and productivity losses account for 3.1% and 11.0% of the differences, respectively.
24
25
26
27
28
29
30
31

32 **DISCUSSION**

33
34 The main results of this cross-sectional, multicentre interview survey demonstrate that
35 total monthly OOP costs and productivity losses of HD (NTD 19,522) were higher than that
36 of PD (NTD 16,392) after adjusting for unemployment rate. The OOP costs for the HD
37 patients were NTD 687 higher than that for the PD patients, with the greatest difference being
38 found in the costs of copayment to hospitalizations and transportation costs. The main
39 sources of the differences between HD and PD patients for productivity losses were seeking
40 outpatient care and time spent operating the dialysis apparatus.
41
42
43
44
45
46
47
48

49 These findings are rarely assessed in previous studies but important for the care of
50 ESRD patients because the OOP costs and productivity losses constitute an important, but
51 frequently omitted, part of the overall evaluation of economic burden borne by patients and
52 their families. Previous studies reported that a significantly higher total NHI-financed
53
54
55
56
57
58
59
60

1
2
3 medical costs were discernible among the HD patients than among the PD patients in several
4 countries, including Taiwan, USA, and UK.^{10 15 23} The total costs per patient-month of HD
5 and PD patients, including the OOP costs and productivity losses (Table 5, Model 1), were
6 NTD 19,522 and NTD 16,392, respectively, with a difference of NTD 3,130 per
7 patient-month. From the payer's perspective, the NHI-financed medical costs of PD seems to
8 be a better cost-saving modality; similarly, from a patient's and societal perspective, the total
9 costs per patient-month of HD were higher owing to higher OOP costs except in the age
10 group more than 70 years old (Table 5).
11
12
13
14
15
16
17
18
19

20 In this study, productivity losses were estimated according to the human capital
21 approach using the reduced future gross income, including lower paid or unpaid production
22 due to seeking medical care and operating the PD apparatus.²¹ Productivity losses accounted
23 for 31.7% of the overall costs in the HD patients, which is similar to 31.8% in the PD patients.
24 The mean difference of the productivity losses after bootstrap procedures between HD and
25 PD patients was NTD 2,539 (Table 4). The results reflected that the productivity losses,
26 resulting from the time spent seeking outpatient care and operating the dialysis apparatus
27 were significantly lower in the PD than in the HD patients. The productivity losses in HD
28 patients decreased gradually in the older age groups and was higher than those of PD patients
29 in the same age group (Table 4). Unlike the HD patients, who needed to visit a HD centre
30 three times a week, the PD patients could work freely and spent less time in operating the
31 dialysis apparatus and had lower productivity losses. When compared to HD, PD is a
32 self-care and time-saving modality, which explains the lower productivity losses. To extend
33 the generalisability of our findings to other national health systems, our result demonstrates
34 that PD modality may appear to be more suitable for its markedly lower productivity losses
35 for countries with a younger dialysis patient population (less than 70 years old), or with a
36 higher value hourly wage or daily wage.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The results of this study confirmed HD modality had higher OOP costs and productivity
4 losses than PD modality shown in previous studies.^{12,20} This study also found that
5 productivity losses contributed 15.2% and 16.5% to the total economic burden of HD and PD,
6 respectively, which were higher than 12.4% and 9.8% found in the Brazilian study.²⁰ This
7 discrepancy may reflect the difference in healthcare system in Taiwan, where medical care is
8 mainly financed by National Health Insurance and in Brazil where patients pay out-of-pocket
9 for their medical care.
10
11

12
13
14
15
16
17
18 The results of this study have some limitations. First, the difference in the proportion of
19 age groups in HD and PD patients are the major drawback of this study. From the 2016
20 Annual Report on Kidney Disease in Taiwan, the mean ages of HD and PD commencement
21 in 2014 were 66.7 and 57.3, respectively, which were older than those of HD and PD patients
22 in this cross-sectional study (61.0 and 56.2, respectively, Table 1).¹⁵ Due to this difference, it
23 was difficult to obtain sampling of these two groups of patients in the similar age range.
24
25
26
27
28
29
30
31 Therefore, we analysed the results by stratifying into four age groups to compare the
32 differences. Second, the results of this study should be interpreted cautiously. The sample size
33 could not represent the general population of HD and PD patients in Taiwan because the
34 sampled patients were also not randomised, although they were sampled from different parts
35 of Taiwan. Third, the impaired productivity or reduced effectiveness at work associated with
36 HD or PD were not included in this study, so the productivity losses may thus have led to an
37 underestimation.
38
39
40
41
42
43
44
45

46
47 In this study, we present a patient interview survey in Taiwan to analyse the OOP costs
48 and productivity losses for HD and PD patients. From a patient's and societal perspective, the
49 HD patients have higher OOP costs and productivity losses than the PD patients in the age
50 group less than 70 years old owing to higher productivity losses.
51
52
53
54

55 **Contributors:** CHT and YMS: study concept and design. HHC, MJW, BGH, JCT, CCK, SPL,
56
57
58
59
60

1
2
3 and THC: acquisition of data. CCK, CHT and YMS: analysis and interpretation. CHT and
4
5 YMS: drafted the manuscript. HHC, MJW, BGH, JCT, SPL, and THC: critical revision of the
6
7 manuscript for important intellectual content. All authors: approved the final paper. CHT and
8
9 YMS are fully responsible for the paper.
10

11
12 **Acknowledgement:** We thank doctors Ming-Kuhn Ruaan, Su-Chen Lin, Jui-Yuan Hung, and
13
14 Wen-Sheng Ko for their assistance in collecting clinical data.
15

16
17 **Funding:** This study was supported by grants from Wan Fang Hospital, Taipei Medical
18
19 University (105TMU-WFH-06 and 107-wf-eva-22).
20

21 **Competing interests:** None declared.
22

23 **Data sharing statement:** All relevant data have been included in the paper.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. *Nephrol Dial Transplant* 2008;23(12):3977-82.
2. United States Renal Data System. USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2014.
3. National Health Insurance Administration, Ministry of Health and Welfare. [Available from: https://www.nhi.gov.tw/Content_List.aspx?n=CF2EDC7144006740&topn=D39E2B72B0BDFA15 accessed June 15 2017.
4. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med* 2011;171(2):110-8.
5. Chang YK, Hsu CC, Hwang SJ, et al. A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. *Medicine (Baltimore)* 2012;91(3):144-51.
6. Karopadi AN, Mason G, Rettore E, et al. The role of economies of scale in the cost of dialysis across the world: a macroeconomic perspective. *Nephrol Dial Transplant* 2014;29(4):885-92.
7. Kao TW, Chang YY, Chen PC, et al. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. *Perit Dial Int* 2013;33(6):671-8.
8. Roggeri A, Roggeri DP, Zocchetti C, et al. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. *J Nephrol* 2017;30(2):263-69.
9. Salonen T, Reina T, Oksa H, et al. Cost analysis of renal replacement therapies in Finland. *Am J Kidney Dis* 2003;42(6):1228-38.
10. Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting--a multicentre study. *Nephrol Dial Transplant* 2008;23(6):1982-9.
11. Hornberger J, Hirth RA. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. *Am J Kidney Dis* 2012;60(2):280-7.
12. Yang F, Lau T, Luo N. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. *Nephrology (Carlton)* 2016;21(8):669-77.
13. Chang YT, Hwang JS, Hung SY, et al. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for

- 1
2
3 comorbidities and propensity score. *Sci Rep* 2016;6:30266.
- 4 14. Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of renal replacement
5 therapy in Austria. *Nephrol Dial Transplant* 2011;26(9):2988-95.
- 6 15. 2016 Annual Report on Kidney Disease in Taiwan. Taipei, Taiwan. 2017.
- 7 16. Wu MS, Wu IW, Shih CP, et al. Establishing a platform for battling end-stage renal
8 disease and continuing quality improvement in dialysis therapy in Taiwan-Taiwan
9 Renal Registry Data System (TWRDS). *Acta Nephrologica* 2011;25(3):148-53.
- 10 17. Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. *J Am Soc*
11 *Nephrol* 2012;23(3):533-44.
- 12 18. Li PK, Chow KM, Van de Luijngaarden MW, et al. Changes in the worldwide
13 epidemiology of peritoneal dialysis. *Nat Rev Nephrol* 2017;13(2):90-103.
- 14 19. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices.
15 *JAMA* 1989;262(20):2879-86.
- 16 20. de Abreu MM, Walker DR, Sesso RC, et al. A cost evaluation of peritoneal dialysis and
17 hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil. *Perit*
18 *Dial Int* 2013;33(3):304-15.
- 19 21. Liljas B. How to calculate indirect costs in economic evaluations. *Pharmacoeconomics*
20 1998;13(1 Pt 1):1-7.
- 21 22. Unemployment rate. : National Statistics, R.O.C. (Taiwan). 2016 [Available from:
22 <https://www.stat.gov.tw/point.asp?index=3> accessed December 31 2016.
- 23 23. Bruns FJ, Seddon P, Saul M, et al. The cost of caring for end-stage kidney disease
24 patients: an analysis based on hospital financial transaction records. *J Am Soc*
25 *Nephrol* 1998;9(5):884-90.
- 26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Patient characteristics of the interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Male gender	156 (50.7)	124 (50.4)	0.96
Age (y)	61.0 [12.7]	56.2 [13.9]	<0.01
<50	68 (22.1)	71 (28.9)	
50-59	79 (25.7)	67 (27.2)	
60-69	76 (24.7)	70 (28.5)	
≥70	85 (27.6)	38 (15.5)	
Comorbidities			
Diabetes mellitus	130 (42.2)	74 (30.1)	<0.01
Hypertension	204 (66.2)	193 (78.5)	<0.01
Cancer	17 (5.5)	7 (2.9)	0.13
Chronic obstructive pulmonary disease	5 (1.6)	2 (0.81)	0.40
Cirrhosis of liver	5 (1.6)	3 (1.2)	0.91
Dementia	3 (1.0)	4 (1.6)	0.50
Cerebrovascular disease	8 (2.6)	6 (2.4)	0.91
Peripheral vascular disease	15 (4.9)	8 (3.25)	0.34
Cardiac dysrhythmia	36 (11.7)	20 (8.1)	0.17
Ischemic heart disease	22 (7.1)	6 (2.4)	0.01
Myocardial infarction	11 (3.6)	8 (3.3)	0.84
Chronic heart failure	13 (4.2)	9 (3.7)	0.74
Cause of end-stage renal disease			
Chronic glomerulonephritis	111 (36.0)	82 (33.3)	0.44
Diabetes mellitus	118 (38.3)	71 (28.9)	0.11
Hypertension	108 (35.1)	52 (21.1)	0.02
Hereditary polycystic kidney disease	10 (3.3)	6 (2.4)	0.83
Chronic tubulointerstitial nephritis	5 (1.6)	7 (2.9)	0.19
Lupus nephritis	4 (1.3)	11 (4.5)	<0.01
Others	51 (16.6)	43 (17.5)	0.21
Marital status			
Singled	45 (14.6)	52 (21.1)	0.18
Married	210 (68.2)	159 (64.6)	
Divorced	25 (8.1)	15 (6.2)	
Widowed	28 (9.1)	20 (8.1)	
Education years			
Below primary school	26 (8.4)	15 (6.1)	0.09
Primary school	77 (25.0)	51 (20.7)	
Junior high school	50 (16.2)	31 (12.6)	

1			
2			
3	Senior high school	88 (28.6)	69 (28.1)
4	College	59 (19.2)	66 (26.8)
5	Above college	8 (2.6)	14 (5.7)
6			
7	Family income (NTD)		0.17
8	<30,000	93 (30.2)	80 (32.5)
9	30,000-49,999	99 (32.1)	61 (24.8)
10	50,000-69,999	61 (19.8)	46 (18.7)
11	70,000-99,999	31 (10.1)	25 (10.1)
12	100,000-149,999	9 (2.9)	23 (9.4)
13	150,000-199,999	6 (2.0)	8 (3.3)
14	≥200,000	9 (2.9)	3 (1.2)
15			
16			
17			

18 Data were number (%) or mean [standard deviation]. HD: haemodialysis; NTD: New Taiwan Dollar; PD:
 19 peritoneal dialysis.
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

Table 2. Dialysis related baseline data of interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Duration of dialysis (month)	87.8 [78.1]	45.4 [38.6]	<0.001
Systolic blood pressure (mmHg)	141.8 [24.7]	141.0 [23.2]	0.58
Diastolic blood pressure (mmHg)	76.1 [12.6]	82.3 [14.9]	<0.001
Heart rate (beats/min)	77.5 [10.3]	81.8 [15.1]	<0.01
Serum albumin (g/dL)	4.0 [0.4]	3.8 [0.7]	<0.001
Serum potassium (mmol/L)	4.8 [0.8]	4.0 [0.6]	<0.001
Kt/V	1.66 [0.54]	1.97 [0.31]	<0.001
Urea reduction ratio	73.9 [6.2]	— —	—
Weekly creatinine clearance (ml/min)	— —	60.1 [12.5]	—
Normalized protein nitrogen appearance	— —	1.0 [0.2]	—
Hemoglobin (g/dL)	10.5 [1.5]	10.1 [1.5]	<0.01
Body mass index	23.7 [4.5]	23.9 [3.9]	0.22

Data were mean [standard deviation]. HD: haemodialysis; PD: peritoneal dialysis.

Table 3. Per patient-month out-of-pocket costs of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	5,922 (12,963)	1,794 (488-4,784)	5,237 (7,571)	2,492 (1,018-5,598)	<0.01
Copayment to outpatient care	103 (377)	0 (0-120)	361 (696)	120 (50-400)	<0.001
Copayment to inpatient care	2,209 (11,093)	0 (0-0)	995 (2,163)	0 (0-1,240)	<0.001
Medicine not covered by NHI	591 (1,832)	0 (0-417)	995 (1,911)	125 (0-1,078)	<0.001
Medical equipment	110 (448)	0 (0-0)	439 (726)	208 (0-675)	<0.001
Chinese medication	27 (175)	0 (0-0)	183 (2,153)	0 (0-0)	0.53
Traditional medicine	38 (257)	0 (0-0)	51 (550)	0 (0-0)	0.35
Nutritional supplements	241 (749)	0 (0-0)	542 (2,398)	0 (0-106)	0.26
Transportation costs	1,028 (1,707)	293 (0-1,495)	191 (229)	143 (16-293)	<0.001
Caregiver costs	1,574 (5,453)	0 (0-0)	1,480 (5,309)	0 (0-0)	0.90
Stratified by age groups					
Age <50 (y)	3,766 (5,785)		2,771 (3,150)		0.32
Age 50-59 (y)	4,902 (14,857)		5,824 (7,484)		<0.001
Age 60-69 (y)	7,337 (14,140)		4,091 (6,072)		0.68
Age ≥70 (y)	7,330 (13,980)		10,922 (12,006)		<0.01
After bootstrap procedures					
Total	5,912 (819)		5,225 (485)		<0.001
Stratified by age groups					
Age <50 (y)	3,787 (686)		2,776 (375)		<0.001
Age 50-59 (y)	4,814 (1,678)		5,827 (870)		<0.001
Age 60-69 (y)	7,270 (1,559)		4,111 (701)		<0.001

Age \geq 70 (y)	7,348 (1,521)	10,932 (1,855)	<0.001
-------------------	---------------	----------------	--------

HD: haemodialysis; IQR: interquartile range; NHI: National health Insurance; NTD, New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

For peer review only

Table 4. Per patient-month productivity losses of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	14,147 (10,746)	13,936 (6,961-20,921)	11,604 (7,949)	10,576 (5,315-16,764)	<0.01
Time spent operating dialysis apparatus	— —	— —	8,655 (6,785)	7,450 (3,138-12,700)	
Seeking outpatient care from patients	11,307 (8,007)	12,874 (0-17,567)	774 (591)	798 (399-1,008)	<0.001
Seeking outpatient care from caregivers	1,608 (5,793)	0 (0-0)	400 (759)	0 (0-833)	<0.001
Seeking inpatient care from patients	799 (1,683)	0 (0-0)	1,037 (1,482)	0 (0-2,918)	0.01
Seeking inpatient care from caregivers	433 (1,251)	0 (0-0)	739 (1,290)	0 (0-733)	<0.001
Stratified by age groups					
Age <50 (y)	19,419 (5,888)		13,177 (7,000)		<0.001
Age 50-59 (y)	19,276 (10,606)		14,424 (7,579)		<0.01
Age 60-69 (y)	17,253 (7,901)		12,826 (6,789)		<0.001
Age ≥70 (y)	2,386 (6,184)		1,207 (1,621)		<0.01
After bootstrap procedures					
Total	14,150 (626)		11,611 (510)		<0.001
Stratified by age groups					
Age <50 (y)	19,381 (715)		13,289 (840)		<0.001
Age 50-59 (y)	19,272 (1,162)		14,415 (878)		<0.001
Age 60-69 (y)	17,212 (857)		12,823 (802)		<0.001
Age ≥70 (y)	2,403 (645)		1,206 (255)		<0.001

HD: haemodialysis; IQR: interquartile range; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

Table 5. Total costs of out-of-pocket costs and productivity losses per patient-month of HD and PD patients after bootstrap analysis (in NTD).

Variables	HD	PD	Difference
(1) Out-of-pocket costs	5,912	5,225	687
Stratified by age groups			
Age <50 (y)	3,787	2,776	1,011
Age 50-59 (y)	4,814	5,827	-1,013
Age 60-69 (y)	7,270	4,111	3,159
Age ≥70 (y)	7,348	10,932	-3,584
(2) Productivity losses adjusted for 3.82% unemployment rate^a	13,610	11,167	2,443
Stratified by age groups			
Age <50 (y)	18,641	12,781	5,860
Age 50-59 (y)	18,536	13,864	4,672
Age 60-69 (y)	16,555	12,333	4,222
Age ≥70 (y)	2,311	1,160	1,151
(3) Total costs, model 1 = (1) + (2)	19,522	16,392	3,130
Stratified by age groups			
Age <50 (y)	22,428	15,557	6,871
Age 50-59 (y)	23,350	19,691	3,659
Age 60-69 (y)	23,825	16,444	7,381
Age ≥70 (y)	9,659	12,092	-2,433
(4) Total costs, model 2 = (1) + (2) x 20% decrement in wages	16,800	14,159	2,641
(5) Total costs, model 3 = (1) + (2) x 30% decrement in wages	15,439	13,042	2,397
(6) Total costs, model 4 = (1) + (2) x 40% decrement in wages	14,078	11,925	2,153

HD: haemodialysis; PD: peritoneal dialysis; NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars).

^a Adjusted for mean Taiwan unemployment rate (3.82%) between April 2015 and March 2016.

Figure Legends

Figure 1. Distribution of NHI-financed medical cost¹⁵, out-of-pocket costs, and productivity losses, in HD and PD modalities, and their differences. NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); HD: haemodialysis; PD: peritoneal dialysis.




Figure 1. Distribution of NHI-financed medical cost 15, out-of-pocket costs, and productivity losses, in HD and PD modalities, and their differences. NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); HD: haemodialysis; PD: peritoneal dialysis.

147x99mm (300 x 300 DPI)

Supplementary Online Content

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Chao-Hsiun Tang, Hsi-Hsien Chen, Ming-Ju Wu, Bang-Gee Hsu, Jer-Chia Tsai, Chi-Cheng Kuo, Shih-Pi Lin, Tso-Hsiao Chen, Yuh-Mou Sue

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

	Monthly income (NTD)	Hourly income (NTD) ^a
Male^b		
15 - 19 years	18,300	103
20 - 24 years	25,680	145
25 - 29 years	33,210	187
30 - 34 years	36,090	203
35 - 39 years	40,470	228
40 - 44 years	43,590	245
45 - 49 years	45,930	259
50 - 54 years	44,280	249
55 - 59 years	43,980	248
60 - 64 years	44,760	252
65 - 69 years	34,740	196
70 & over	0	0
Female^b		
15 - 19 years	16,590	96
20 - 24 years	24,600	143
25 - 29 years	30,420	176
30 - 34 years	32,520	189
35 - 39 years	34,440	200
40 - 44 years	36,000	209
45 - 49 years	36,930	214
50 - 54 years	35,850	208
55 - 59 years	34,830	202
60 - 64 years	34,440	200
65 - 69 years	23,100	134
70 & over	0	0
Caregivers^b	36,510	208

NTD, New Taiwan Dollar, 1 US Dollar = 30 New Taiwan Dollars.

^a Average hourly income = average monthly income / average monthly working hours.

^b Average monthly working hours: male = 177.6 hrs.; female = 172.5 hrs.; caregivers = 175.3 hrs.

BMJ Open

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023062.R1
Article Type:	Research
Date Submitted by the Author:	15-Sep-2018
Complete List of Authors:	Tang, Chao-Hsiun ; Taipei Medical University, School of Health Care Administration, College of Management Chen, Hsi-Hsien; Taipei Medical University Hospital, Division of Nephrology, Department of Internal Medicine, Wu, Ming-Ju; Taichung Veterans General Hospital, Division of Nephrology, Department of Internal Medicine Hsu, Bang-Gee ; Buddhist Tzu Chi General Hospital, Division of Nephrology, Department of Internal Medicine Tsai, Jer-Chia ; Kaohsiung Medical University Chung Ho Memorial Hospital, Department of Internal Medicine Kuo, Chi-Cheng; Taipei Medical University, School of Health Care Administration, College of Management Lin, Ship-Pi; Lenity Clinic, Lenity Clinic Chen, Tso-Hsiao ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, SUE, YUH-MOU; School of Medicine, College of Medicine, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine,
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Medical management
Keywords:	cost, haemodialysis, out-of-pocket cost, peritoneal dialysis, productivity loss

SCHOLARONE™
Manuscripts

1
2
3 **Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis**
4 **from a patient interview survey in Taiwan**

5 **Running title:** Costs of HD and PD in Taiwan

6
7
8 **Authors:**

9
10 Chao-Hsiun Tang, PhD¹, Hsi-Hsien Chen, MD, PhD², Ming-Ju Wu, MD, PhD³, Bang-Gee Hsu,
11 MD, PhD⁴, Jer-Chia Tsai, MD⁵, Chi-Cheng Kuo, MBA¹, Shih-Pi Lin, MD⁶, Tso-Hsiao Chen,
12 MD, PhD⁷, Yuh-Mou Sue, MD⁷

13
14
15 **Affiliations:**

16
17 ¹School of Health Care Administration, College of Management, Taipei Medical University,
18 Taipei, Taiwan

19
20 ²Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
21 Medicine and Division of Nephrology, Department of Internal Medicine, Taipei Medical
22 University Hospital, Taipei Medical University, Taipei, Taiwan

23
24 ³Division of Nephrology, Department of Internal Medicine, Taichung Veterans General
25 Hospital, Taichung, Taiwan

26
27 ⁴Division of Nephrology, Department of Internal Medicine, Buddhist Tzu Chi General
28 Hospital and School of Medicine, Tzu Chi University, Hualien, Taiwan

29
30 ⁵Department of Internal Medicine, Kaohsiung Medical University Hospital and Faculty of
31 Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

32
33 ⁶Lenity Clinic, Kaohsiung, Taiwan

34
35 ⁷Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
36 Medicine and Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital,
37 Taipei Medical University, Taipei, Taiwan

38
39
40
41
42
43
44 **Correspondence:** Yuh-Mou Sue, MD, Division of Nephrology, Department of Internal
45 Medicine, Wan Fang Hospital, Taipei Medical University, 5th Floor, 111 Xing Long Road,
46 Section 3, Taipei 116, Taiwan

47
48
49 E-mail: sueym@tmu.edu.tw; Tel: 886-2-29307930-8103; Fax: 886-2-29302448

ABSTRACT

Objectives: The total medical (economic) costs of haemodialysis (HD) and peritoneal dialysis (PD), including direct medical costs, out-of-pocket (OOP) costs, and productivity losses, have become an important issue. This study aims to compare the direct non-medical costs and indirect medical costs of both modalities in Taiwan.

Design and Setting: This multicentre study included cross-sectional interviews of patients over 20 years old and articulate, who had been continuously receiving long-term HD or PD for more than three months between April 2015 and March 2016. Mann-Whitney U test, Wilcoxon rank sum test, and 1,000 bootstrap procedures with replacement were used for analysis.

Outcome measures: Differences in OOP costs and productivity losses.

Results: There were 308 HD and 246 PD patients available for analysis. HD patients had significantly higher monthly OOP costs than PD patients after bootstrap procedures (NTD 5,912 vs. NTD 5,225, $p < 0.001$; NTD, New Taiwan Dollars; 1 US Dollar = 30 NTD). Compared with PD patients, HD patients had higher monthly productivity losses after bootstrap procedures (NTD 14,150 vs. NTD 11,611, $p < 0.001$), resulting from more time spent seeking outpatient care (HD, 70.4 hours vs. PD, 4.4 hours, $p < 0.001$) and time spent by family caregivers for outpatient care (HD, 66.1 hours vs. PD, 6.1 hours, $p < 0.001$). The total costs per patient-month of HD and PD modalities, including OOP costs and productivity losses were NTD 20,062 and NTD 16,836, respectively.

Conclusions: The HD modality has higher OOP costs and productivity losses than the PD modality in Taiwan.

Keywords: cost, haemodialysis; out-of-pocket cost; peritoneal dialysis; productivity loss

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This multicentre study included cross-sectional interviews of long-term HD and PD patients.
- Previous study seldom assessed the information about out-of-pocket payments and productivity losses collected from patient undergoing HD and PD.
- The difference in the proportion of age groups in HD and PD patients are the major drawback of this study.
- The sample size could not represent the general population of HD and PD patients in Taiwan because the sampled patients were also not randomised

INTRODUCTION

Since March 1995, when Taiwan began implementing the National Health Insurance (NHI) system, the per capita healthcare expenditure has increased annually, especially in the care of 'end-stage renal disease' (ESRD) patients. Taiwan has the highest incidence and prevalence rates of ESRD in the world.¹⁻³ By 2017, the cost of dialysis (New Taiwan Dollar, NTD 36.9 billion; 1 US dollar = 30 NTDs in Dec. 2017) accounted for a staggering 5.73% of the total annual NHI expenditure (NTD 644.1 billion).³ Haemodialysis (HD) and peritoneal dialysis (PD) are the two major renal replacement modalities in Taiwan with a similar all-cause mortality rate.⁴⁻⁷ Several studies have provided clear evidence that HD has the higher direct medical costs among the two modalities.⁸⁻¹⁴ NHI administrators implemented several strategies besides applying a blanket budget cap on dialysis expenditure to contain the total costs of dialysis and incentivize the use of PD modality. These efforts included increasing the reimbursements for PD and extending the NHI payment scheme covering the automated PD machine costs. As the proportion of PD usage increases, its prevalence in Taiwan has been gradually increasing, from 6.5% in 2003 to 8.5% in 2007, and up to 9.2% in 2014, similar to the average level within the developed countries.¹⁵⁻¹⁸

ESRD prevalence is increasing with the rise in the number of aging and diabetic nephropathy patients. The total (economic) costs of HD and PD modalities, including direct medical costs, direct non-medical costs, and productivity losses, have become an important issue.¹⁹ Direct medical costs incurred for medical services, such as dialysis costs, physician and nurses' services, diagnostic tests, and hospitalization costs, are the most common type cited in the nephrologic literature. From a payer's perspective (e.g., national insurance organizations), these costs are the most important. However, from a patient's as well as societal perspectives, out-of-pocket (OOP) costs and productivity losses are nominal and meaningful. OOP costs and productivity losses have not been assessed comprehensively in

1
2
3 ESRD patients for two reasons: the methods for collecting these data for the ESRD patients
4 are not well established, and retrospective data collection is difficult. Only two studies have
5 reported that PD had less OOP costs and productivity losses than HD in Brazil and Singapore,
6 but detailed data were not stated.^{12 20} These studies highlighted a significant economic burden
7 due to dialysis and a higher direct healthcare costs associated with the use of HD modality;
8 however, little information is available about OOP costs, including expenses on caregivers or
9 transportation, as well as productivity losses, including job loss, worker replacement, and
10 reduced productivity from patients and family. According to the 2016 Annual Report on
11 Kidney Disease in Taiwan, HD patients had higher NHI expenses (NTD 70,000 per
12 patient-month) than PD patients (NTD 51,000 per patient-month), owing to higher cost of
13 outpatient care (HD, NTD 56,000 per patient-month; PD, NTD 43,000 per patient-month)
14 and inpatient care (HD, NTD 13,400 per patient-month; PD, NTD 8,200 per patient-month).¹⁵
15
16 However, the extent to which OOP costs and productivity losses contribute to the overall
17 economic burden of HD and PD are yet to be explored in Taiwan. We, therefore, conducted
18 this study from a patient's and societal perspectives, using face-to-face interviews to compare
19 OOP costs and productivity losses between HD and PD patients in Taiwan.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **METHODS**

40 **Study Design**

41
42
43 Ours was a multicentre study using cross-sectional interviews with patients over 20
44 years old, carried out at the nephrology outpatient clinics of five hospitals and five dialysis
45 clinics located in northern, central, southern, and eastern Taiwan between April 2015 and
46 March 2016. The Joint Institutional Review Board of Taipei Medical University approved
47 this study (No. 201503057). All participants provided informed consent to participate in this
48 study. All aspects of the study were performed in accordance with relevant guidelines and
49 regulations.
50
51
52
53
54
55
56
57
58
59
60

Patient and Public Involvement

No patients were asked for input in the creation of this article.

Sampling

Articulate ESRD patients who were receiving long-term HD or PD continuously for more than three months were chosen. Those aged less than 20 years or unable to communicate were excluded. Patients were recruited and enrolled using a 1:1 male-to-female enrolment design. A total of 581 ESRD patients were screened at the contributing sites, of whom 554 were eligible and enrolled. In total, there were 308 HD patients (156 men, 152 women) and 246 PD patients (124 men, 122 women; 117 automated PD, 129 continuous ambulatory PD) available for analysis.

The patient interviews were performed face by face by well-trained nurses from the site or graduate students from the Taipei Medical University during HD therapy or monthly PD clinic visit. All interviewers had attended prior interviewer training. The patients' baseline characteristics were collected from their medical chart and own response. The patient details collected include sociodemographics, comorbidities, cause of ESRD, and dialysis data (Table 1 and 2). We examine the differences in OOP costs and productivity losses between HD and PD patients. OOP costs included all expenses related to ESRD paid by the patients/family and not reimbursed by the NHI, such as expenses for medicines, medical materials and devices, herbal and alternative medicines, nutritional supplements, transportation costs, and caregiver costs. By using the 'human capital approach',²¹ productivity losses were valued and measured by multiplying the loss of time in hours or days with average hourly/daily wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan (see supplementary Table S1). There were two sources of time loss being evaluated: patients' and caregivers' time spent in seeking care and time spent in operating the dialysis apparatus at home.

Statistical Analysis

1
2
3 The analyses began with a baseline comparison of patients receiving either HD or PD
4 therapy. Frequencies for categorical variables and means with standard deviations or medians
5 with interquartile ranges for continuous variables were calculated. Statistical differences
6 between the HD and PD patients were determined with Chi-square (χ^2) tests, Mann-Whitney
7 U test and Wilcoxon rank sum test as appropriate to analyse the patient interview survey data.
8
9 Finally, as patient characteristics and costs may differ outside clinical settings and in different
10 conditions, a bootstrap analysis was further performed on OOP costs and productivity losses,
11 by applying 1,000 bootstrap procedures of HD and PD patients with replacement, stratified
12 by age groups. The difference between the groups was significant for the two-sided p -value
13 <0.05 . All the analyses in this study were carried out using the SAS 9.3 software (SAS
14 Institute Inc., Cary, NC, USA).

25 **Sensitivity Analysis**

26
27
28 Moreover, the HD and PD patients are a group of patients with a debilitating illness and
29 may receive lower wage rates than the general population resulting in lower productivity
30 losses. To assess the impact of productivity losses on the sum of OOP costs and productivity
31 losses, we adjusted the productivity losses for the mean Taiwan unemployment rate (3.82%)
32 during the interview period (between April 2015 and March 2016) and then set the
33 productivity losses with a 20%, 30%, or 40% decrement of wages as different scenarios to
34 calculate the total amount of these two costs.²²

35 **RESULTS**

36
37
38 A total of 308 HD patients and 246 PD patients were interviewed in the multicentre
39 cross-sectional study. Patient baseline characteristics are shown in Table 1. HD patients were
40 older as more patients were over 70 years old. Diabetes and ischemic heart disease
41 prevalence was higher and hypertension was lower in HD patients. Hypertension and lupus
42 nephritis had a discernibly different causation of ESRD between the HD and PD patients.

1
2
3 Marital status, education, and income were not statistically different between the groups. The
4 dialysis-related baseline data are reported in Table 2, where the maximum differences were
5 found to be the duration of dialysis, haemoglobin, serum albumin, and potassium.
6
7

8
9 Table 3 shows the results of the per patient-month OOP costs. There were discernible
10 differences between the HD and PD patients in the OOP costs (NTD 5,922 vs. NTD 5,237, p
11 <0.01). The HD patients had significantly lower copayment for outpatient visits, medicine not
12 covered by NHI, and medical equipment, but higher copayment for hospitalizations and
13 transportation than the PD patients. Chinese medication, traditional medicine, and nutritional
14 supplements showed no discernible differences between groups. Another main source of the
15 differences between the HD and PD patients were the transportation costs, owing to more
16 frequent transportation in the former group. However, the results of the mean OOP costs were
17 not consistent in each age group. PD patients had significantly higher OOP costs than the
18 corresponding HD patients in the age groups of 50–59 years old and over 70 years old.
19
20

21
22 Results of the per patient-month productivity losses are reported in Table 4. Compared
23 with the PD patients, the HD patients had higher monthly productivity losses (NTD 14,147 vs.
24 NTD 11,604, $p <0.01$), resulting from more time spent seeking outpatient care (HD, $70.4 \pm$
25 6.9 hours vs. PD, 4.4 ± 2.5 hours, $p <0.001$) and time spent by family caregivers for
26 outpatient care (HD, 66.1 ± 51.5 hours vs. PD, 6.1 ± 4.1 hours, $p <0.001$). However, only
27 10.4% and 31.3% of HD and PD patients, respectively, had family caregivers who
28 accompanied them for outpatient care. The productivity losses resulting from time spent
29 operating the dialysis apparatus (49.9 ± 27.8 hours) were only seen in PD patients but not HD
30 patients. After the 1,000 bootstrap procedures, the results of the mean productivity losses
31 remained unchanged in each age group. HD patients had significantly lower productivity
32 losses in the age group over 70 years old because no productivity losses were included
33 beyond the age of 70 years.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Table 5 reports the total costs per patient-month, including OOP costs and productivity
4 losses. The productivity losses were further adjusted for mean Taiwan unemployment rate
5 (3.82%) during the interview survey periods. Models 2–4 show the total costs including OOP
6 costs and productivity losses adjusted for unemployment rate with a 20%, 30%, or 40%
7 decrement of wages as different scenarios. After considering the productivity losses under
8 various scenarios, the differences of total costs between the HD and PD patients slightly
9 decreased in Models 2–4. After stratified by age groups, the total costs per patient-month of
10 HD patients were higher than those of PD patients except in the age group older than 70 years
11 old.
12
13
14
15
16
17
18
19
20
21

22 Incorporating the NHI-financed medical costs of HD and PD reported in the 2016
23 Annual Report on Kidney Disease in Taiwan into the findings in this study¹⁵, Figure 1 shows
24 the per patient-month total costs are NTD 90,062 for HD and NTD 67,836 for PD, to which
25 OOP costs contributed 6.6% and 7.7%, and productivity losses 15.7% and 17.1%,
26 respectively. For the NTD 22,227 per-patient-month difference in the costs of HD and PD,
27 OOP and productivity losses account for 3.1% and 11.4% of the differences, respectively.
28
29
30
31
32
33
34
35
36

37 **DISCUSSION**

38
39 The main results of this cross-sectional, multicentre interview survey demonstrate that
40 total monthly OOP costs and productivity losses of HD (NTD 19,522) were higher than that
41 of PD (NTD 16,392) after adjusting for unemployment rate. The OOP costs for the HD
42 patients were NTD 687 higher than that for the PD patients, with the greatest difference being
43 found in the costs of copayment to hospitalizations and transportation costs. The main
44 sources of the differences between HD and PD patients for productivity losses were seeking
45 outpatient care and time spent operating the dialysis apparatus. The total economic costs of
46 HD (NT 90,062), including NHI expenses, OPP costs and productivity losses, were higher
47 than those of PD (NT 67,836), which were most contributed by NHI expenses (NT 19,000,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 85.5%) (Figure 1).
4

5 These findings are rarely assessed in previous studies but important for the care of
6
7 ESRD patients because the OOP costs and productivity losses constitute an important, but
8
9 frequently omitted, part of the overall evaluation of economic burden borne by patients and
10
11 their families. Previous studies reported that a significantly higher total NHI-financed
12
13 medical costs were discernible among the HD patients than among the PD patients in several
14
15 countries, including Taiwan, USA, and UK.^{10 15 23} The total costs per patient-month of HD
16
17 and PD patients, including the OOP costs and productivity losses (Table 5, Model 1), were
18
19 NTD 20,063 and NTD 16,836, respectively, with a difference of NTD 3,227 per
20
21 patient-month. From the payer's perspective, the NHI-financed medical costs of PD seems to
22
23 be a better cost-saving modality; similarly, from a patient's and societal perspective, the total
24
25 costs per patient-month of HD were higher owing to higher OOP costs except in the age
26
27 group more than 70 years old (Table 5). Aged ESRD patients often have comorbidities, such
28
29 as diabetes mellitus with retinopathy and poor vision acuity. Considering the necessity of
30
31 caregiver's support to complete the every day's procedures, most patients would not choose
32
33 PD as a favour choice to prevent the OOP cost of caregiver. Compared with HD patients, PD
34
35 patients with diabetes mellitus or age more than 65 years old also had increased death rate.
36
37 All these factors would discourage patients to choosing PD as their renal replacement
38
39 modality.⁵
40
41
42
43

44 In this study, productivity losses were estimated according to the human capital
45
46 approach using the reduced future gross income, including lower paid or unpaid production
47
48 due to seeking medical care and operating the PD apparatus.²¹ Productivity losses accounted
49
50 for 31.7% of the overall costs in the HD patients, which is similar to 31.8% in the PD patients.
51
52 The mean difference of the productivity losses after bootstrap procedures between HD and
53
54 PD patients was NTD 2,539 (Table 4). The results reflected that the productivity losses,
55
56
57
58
59
60

1
2
3 resulting from the time spent seeking outpatient care and operating the dialysis apparatus
4
5 were significantly lower in the PD than in the HD patients. The productivity losses in HD
6
7 patients decreased gradually in the older age groups and was higher than those of PD patients
8
9 in the same age group (Table 4). Unlike the HD patients, who needed to visit a HD centre
10
11 three times a week, the PD patients could work freely and spent less time in operating the
12
13 dialysis apparatus and had lower productivity losses. When compared to HD, PD is a
14
15 self-care and time-saving modality, which explains the lower productivity losses. In patients
16
17 with chronic kidney disease stage 5 near ESRD, facing with numerous decisions across the
18
19 trajectory of their illness are needed. Using shared decision making approach offers a
20
21 patient-centered method to nudge patients facing health-related decisions, including the
22
23 choice of HD, PD, kidney transplantation or hospice care. The OPP costs and productivity
24
25 losses have significant impact on quality of lives and cost of healthcare delivery. Exploring
26
27 the detailed information will provide evidence based, high-quality decision aids and be able
28
29 to meet patients' informational needs. To extend the generalisability of our findings to other
30
31 national health systems, our result demonstrates that PD modality may appear to be more
32
33 suitable for its markedly lower productivity losses for countries with a younger dialysis
34
35 patient population (less than 70 years old), or with a higher value hourly wage or daily wage.
36
37
38

39
40 The results of this study confirmed HD modality had higher OOP costs and productivity
41
42 losses than PD modality shown in previous studies.^{12 20} This study also found that
43
44 productivity losses contributed 15.2% and 16.5% to the total economic burden of HD and PD,
45
46 respectively, which were higher than 12.4% and 9.8% found in the Brazilian study.²⁰ This
47
48 discrepancy may reflect the difference in healthcare system in Taiwan, where medical care is
49
50 mainly financed by National Health Insurance and in Brazil where patients pay out-of-pocket
51
52 for their medical care.
53

54
55 The results of this study have some limitations. First, the difference in the proportion of
56
57
58
59
60

1
2
3 age groups in HD and PD patients are the major drawback of this study. From the 2016
4 Annual Report on Kidney Disease in Taiwan, the mean ages of HD and PD commencement
5 in 2014 were 66.7 and 57.3, respectively, which were older than those of HD and PD patients
6 in this cross-sectional study (61.0 and 56.2, respectively, Table 1).¹⁵ Due to this difference, it
7 was difficult to obtain sampling of these two groups of patients in the similar age range.
8
9 Therefore, we analysed the results by stratifying into four age groups to compare the
10 differences. Second, the results of this study should be interpreted cautiously. The sample size
11 could not represent the general population of HD and PD patients in Taiwan because the
12 sampled patients were also not randomised, although they were sampled from different parts
13 of Taiwan. Third, the impaired productivity or reduced effectiveness at work associated with
14 HD or PD were not included in this study, so the productivity losses may thus have led to an
15 underestimation.
16
17

18
19
20 In this study, we present a patient interview survey in Taiwan to analyse the OOP costs
21 and productivity losses for HD and PD patients. From a patient's and societal perspective, the
22 HD patients have higher OOP costs and productivity losses than the PD patients in the age
23 group less than 70 years old owing to higher productivity losses.
24
25

26
27
28 **Contributors:** CHT and YMS: study concept and design. HHC, MJW, BGH, JCT, CCK, SPL,
29 and THC: acquisition of data. CCK, CHT and YMS: analysis and interpretation. CHT and
30 YMS: drafted the manuscript. HHC, MJW, BGH, JCT, SPL, and THC: critical revision of the
31 manuscript for important intellectual content. All authors: approved the final paper. CHT and
32 YMS are fully responsible for the paper.
33
34

35
36
37 **Acknowledgement:** We thank doctors Ming-Kuhn Ruaan, Su-Chen Lin, Jui-Yuan Hung, and
38 Wen-Sheng Ko for their assistance in collecting clinical data.
39
40

41
42
43 **Funding:** This study was supported by grants from Wan Fang Hospital, Taipei Medical
44 University (105TMU-WFH-05).
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests: None declared.

Data sharing statement: All relevant data have been included in the paper.

For peer review only

REFERENCES

1. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. *Nephrol Dial Transplant* 2008;23(12):3977-82.
2. United States Renal Data System. USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2014.
3. National Health Insurance Administration, Ministry of Health and Welfare. [Available from: https://www.nhi.gov.tw/Content_List.aspx?n=CF2EDC7144006740&topn=D39E2B72B0BDFA15 accessed June 15 2017.
4. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med* 2011;171(2):110-8.
5. Chang YK, Hsu CC, Hwang SJ, et al. A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. *Medicine (Baltimore)* 2012;91(3):144-51.
6. Karopadi AN, Mason G, Rettore E, et al. The role of economies of scale in the cost of dialysis across the world: a macroeconomic perspective. *Nephrol Dial Transplant* 2014;29(4):885-92.
7. Kao TW, Chang YY, Chen PC, et al. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. *Perit Dial Int* 2013;33(6):671-8.
8. Roggeri A, Roggeri DP, Zocchetti C, et al. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. *J Nephrol* 2017;30(2):263-69.
9. Salonen T, Reina T, Oksa H, et al. Cost analysis of renal replacement therapies in Finland. *Am J Kidney Dis* 2003;42(6):1228-38.
10. Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting--a multicentre study. *Nephrol Dial Transplant* 2008;23(6):1982-9.
11. Hornberger J, Hirth RA. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. *Am J Kidney Dis* 2012;60(2):280-7.
12. Yang F, Lau T, Luo N. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. *Nephrology (Carlton)* 2016;21(8):669-77.
13. Chang YT, Hwang JS, Hung SY, et al. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for

- 1
2
3 comorbidities and propensity score. *Sci Rep* 2016;6:30266.
- 4 14. Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of renal replacement
5 therapy in Austria. *Nephrol Dial Transplant* 2011;26(9):2988-95.
- 6 15. 2016 Annual Report on Kidney Disease in Taiwan. Taipei, Taiwan. 2017.
- 7 16. Wu MS, Wu IW, Shih CP, et al. Establishing a platform for battling end-stage renal
8 disease and continuing quality improvement in dialysis therapy in Taiwan-Taiwan
9 Renal Registry Data System (TWRDS). *Acta Nephrologica* 2011;25(3):148-53.
- 10 17. Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. *J Am Soc*
11 *Nephrol* 2012;23(3):533-44.
- 12 18. Li PK, Chow KM, Van de Luijngaarden MW, et al. Changes in the worldwide
13 epidemiology of peritoneal dialysis. *Nat Rev Nephrol* 2017;13(2):90-103.
- 14 19. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices.
15 *JAMA* 1989;262(20):2879-86.
- 16 20. de Abreu MM, Walker DR, Sesso RC, et al. A cost evaluation of peritoneal dialysis and
17 hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil. *Perit*
18 *Dial Int* 2013;33(3):304-15.
- 19 21. Liljas B. How to calculate indirect costs in economic evaluations. *Pharmacoeconomics*
20 1998;13(1 Pt 1):1-7.
- 21 22. Unemployment rate. : National Statistics, R.O.C. (Taiwan). 2016 [Available from:
22 <https://www.stat.gov.tw/point.asp?index=3> accessed December 31 2016.
- 23 23. Bruns FJ, Seddon P, Saul M, et al. The cost of caring for end-stage kidney disease
24 patients: an analysis based on hospital financial transaction records. *J Am Soc*
25 *Nephrol* 1998;9(5):884-90.
- 26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Patient characteristics of the interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Male gender	156 (50.7)	124 (50.4)	0.96
Age (y)	61.0 [12.7]	56.2 [13.9]	<0.01
<50	68 (22.1)	71 (28.9)	
50-59	79 (25.7)	67 (27.2)	
60-69	76 (24.7)	70 (28.5)	
≥70	85 (27.6)	38 (15.5)	
Comorbidities			
Diabetes mellitus	130 (42.2)	74 (30.1)	<0.01
Hypertension	204 (66.2)	193 (78.5)	<0.01
Cancer	17 (5.5)	7 (2.9)	0.13
Chronic obstructive pulmonary disease	5 (1.6)	2 (0.81)	0.40
Cirrhosis of liver	5 (1.6)	3 (1.2)	0.91
Dementia	3 (1.0)	4 (1.6)	0.50
Cerebrovascular disease	8 (2.6)	6 (2.4)	0.91
Peripheral vascular disease	15 (4.9)	8 (3.25)	0.34
Cardiac dysrhythmia	36 (11.7)	20 (8.1)	0.17
Ischemic heart disease	22 (7.1)	6 (2.4)	0.01
Myocardial infarction	11 (3.6)	8 (3.3)	0.84
Chronic heart failure	13 (4.2)	9 (3.7)	0.74
Cause of end-stage renal disease			
Chronic glomerulonephritis	111 (36.0)	82 (33.3)	0.44
Diabetes mellitus	118 (38.3)	71 (28.9)	0.11
Hypertension	108 (35.1)	52 (21.1)	0.02
Hereditary polycystic kidney disease	10 (3.3)	6 (2.4)	0.83
Chronic tubulointerstitial nephritis	5 (1.6)	7 (2.9)	0.19
Lupus nephritis	4 (1.3)	11 (4.5)	<0.01
Others	51 (16.6)	43 (17.5)	0.21
Marital status			
			0.18
Singled	45 (14.6)	52 (21.1)	
Married	210 (68.2)	159 (64.6)	
Divorced	25 (8.1)	15 (6.2)	
Widowed	28 (9.1)	20 (8.1)	
Education years			
			0.09
Below primary school	26 (8.4)	15 (6.1)	
Primary school	77 (25.0)	51 (20.7)	
Junior high school	50 (16.2)	31 (12.6)	

1				
2				
3	Senior high school	88 (28.6)	69 (28.1)	
4	College	59 (19.2)	66 (26.8)	
5	Above college	8 (2.6)	14 (5.7)	
6				
7	Family income (NTD)			0.17
8	<30,000	93 (30.2)	80 (32.5)	
9	30,000-49,999	99 (32.1)	61 (24.8)	
10	50,000-69,999	61 (19.8)	46 (18.7)	
11	70,000-99,999	31 (10.1)	25 (10.1)	
12	100,000-149,999	9 (2.9)	23 (9.4)	
13	150,000-199,999	6 (2.0)	8 (3.3)	
14	≥200,000	9 (2.9)	3 (1.2)	

18 Data were number (%) or mean [standard deviation]. HD: haemodialysis; NTD: New Taiwan Dollar; PD:
 19 peritoneal dialysis.
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

Table 2. Dialysis related baseline data of interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Duration of dialysis (month)	63 (26-135)	37 (16-63)	<0.001
Systolic blood pressure (mmHg)	141.8 [24.7]	141.0 [23.2]	0.58
Diastolic blood pressure (mmHg)	76.1 [12.6]	82.3 [14.9]	<0.001
Heart rate (beats/min)	77.5 [10.3]	81.8 [15.1]	<0.01
Serum albumin (g/dL)	4.0 [0.4]	3.8 [0.7]	<0.001
Serum potassium (mmol/L)	4.8 [0.8]	4.0 [0.6]	<0.001
Standard Kt/V (HD) or Kt/V (PD)	2.39 [0.32]	1.97 [0.31]	<0.001
Urea reduction ratio	73.9 [6.2]	— —	—
Weekly creatinine clearance (ml/min)	— —	60.1 [12.5]	—
Normalized protein nitrogen appearance	— —	1.0 [0.2]	—
Hemoglobin (g/dL)	10.5 [1.5]	10.1 [1.5]	<0.01
Body mass index	23.7 [4.5]	23.9 [3.9]	0.22

Data were median (interquartile range) or mean [standard deviation]. HD: haemodialysis; PD: peritoneal dialysis.

Table 3. Per patient-month out-of-pocket costs of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		p-value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	5,922 (12,963)	1,794 (488-4,784)	5,237 (7,571)	2,492 (1,018-5,598)	<0.01
Copayment to outpatient care	103 (377)	0 (0-120)	361 (696)	120 (50-400)	<0.001
Copayment to inpatient care	2,209 (11,093)	0 (0-0)	995 (2,163)	0 (0-1,240)	<0.001
Medicine not covered by NHI	591 (1,832)	0 (0-417)	995 (1,911)	125 (0-1,078)	<0.001
Medical equipment	110 (448)	0 (0-0)	439 (726)	208 (0-675)	<0.001
Chinese medication	27 (175)	0 (0-0)	183 (2,153)	0 (0-0)	0.53
Traditional medicine	38 (257)	0 (0-0)	51 (550)	0 (0-0)	0.35
Nutritional supplements	241 (749)	0 (0-0)	542 (2,398)	0 (0-106)	0.26
Transportation costs	1,028 (1,707)	293 (0-1,495)	191 (229)	143 (16-293)	<0.001
Caregiver costs	1,574 (5,453)	0 (0-0)	1,480 (5,309)	0 (0-0)	0.90
Stratified by age groups					
Age <50 (y)	3,766 (5,785)		2,771 (3,150)		0.32
Age 50-59 (y)	4,902 (14,857)		5,824 (7,484)		<0.001
Age 60-69 (y)	7,337 (14,140)		4,091 (6,072)		0.68
Age ≥70 (y)	7,330 (13,980)		10,922 (12,006)		<0.01
After bootstrap procedures					
Total	5,912 (819)		5,225 (485)		<0.001
Stratified by age groups					
Age <50 (y)	3,787 (686)		2,776 (375)		<0.001
Age 50-59 (y)	4,814 (1,678)		5,827 (870)		<0.001
Age 60-69 (y)	7,270 (1,559)		4,111 (701)		<0.001

1
2
3
4
5 Age \geq 70 (y) 7,348 (1,521) 10,932 (1,855) <0.001

6 HD: haemodialysis; IQR: interquartile range; NHI: National health Insurance; NTD, New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD:
7 peritoneal dialysis; SD: standard deviation.
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 4. Per patient-month productivity losses of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	14,147 (10,746)	13,936 (6,961-20,921)	11,604 (7,949)	10,576 (5,315-16,764)	<0.01
Time spent operating dialysis apparatus	— —	— —	8,655 (6,785)	7,450 (3,138-12,700)	
Seeking outpatient care from patients	11,307 (8,007)	12,874 (0-17,567)	774 (591)	798 (399-1,008)	<0.001
Seeking outpatient care from caregivers	1,608 (5,793)	0 (0-0)	400 (759)	0 (0-833)	<0.001
Seeking inpatient care from patients	799 (1,683)	0 (0-0)	1,037 (1,482)	0 (0-2,918)	0.01
Seeking inpatient care from caregivers	433 (1,251)	0 (0-0)	739 (1,290)	0 (0-733)	<0.001
Stratified by age groups					
Age <50 (y)	19,419 (5,888)		13,177 (7,000)		<0.001
Age 50-59 (y)	19,276 (10,606)		14,424 (7,579)		<0.01
Age 60-69 (y)	17,253 (7,901)		12,826 (6,789)		<0.001
Age ≥70 (y)	2,386 (6,184)		1,207 (1,621)		<0.01
After bootstrap procedures					
Total	14,150 (626)		11,611 (510)		<0.001
Stratified by age groups					
Age <50 (y)	19,381 (715)		13,289 (840)		<0.001
Age 50-59 (y)	19,272 (1,162)		14,415 (878)		<0.001
Age 60-69 (y)	17,212 (857)		12,823 (802)		<0.001
Age ≥70 (y)	2,403 (645)		1,206 (255)		<0.001

HD: haemodialysis; IQR: interquartile range; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

Table 5. Total costs of out-of-pocket costs and productivity losses per patient-month of HD and PD patients after bootstrap analysis (in NTD).


Variables	HD	PD	Difference
(1) Out-of-pocket costs	5,912	5,225	687
Stratified by age groups			
Age <50 (y)	3,787	2,776	1,011
Age 50-59 (y)	4,814	5,827	-1,013
Age 60-69 (y)	7,270	4,111	3,159
Age ≥70 (y)	7,348	10,932	-3,584
(2) Productivity losses	14,150	11,611	2,540
Stratified by age groups			
Age <50 (y)	19,381	13,289	6,093
Age 50-59 (y)	19,272	14,415	4,858
Age 60-69 (y)	17,213	12,823	4,390
Age ≥70 (y)	2,403	1,206	1,197
(3) Total costs			
Model 1 = (1) + (2)	20,062	16,836	3,227
Stratified by age groups			
Age <50 (y)	23,168	16,065	7,103
Age 50-59 (y)	24,086	20,242	3,844
Age 60-69 (y)	24,483	16,934	7,549
Age ≥70 (y)	9,751	12,138	-2,387
Model 2 = (1) + (2) x 20% decrement in wages x (1-0.0382)^a	16,800	14,159	2,641
Model 3 = (1) + (2) x 30% decrement in wages x (1-0.0382)^a	15,439	13,042	2,397
Model 4 = (1) + (2) x 40% decrement in wages x (1-0.0382)^a	14,078	11,925	2,153

HD: haemodialysis; PD: peritoneal dialysis; NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars).

^a Adjusted for mean Taiwan unemployment rate (3.82%) between April 2015 and March 2016.

Figure Legends

Figure 1. Distribution of NHI-financed medical cost¹⁵, out-of-pocket costs, and productivity losses, in HD and PD modalities, and their differences. NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); HD: haemodialysis; PD: peritoneal dialysis.



221x150mm (300 x 300 DPI)

Supplementary Online Content

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Chao-Hsiun Tang, Hsi-Hsien Chen, Ming-Ju Wu, Bang-Gee Hsu, Jer-Chia Tsai, Chi-Cheng Kuo, Shih-Pi Lin, Tso-Hsiao Chen, Yuh-Mou Sue

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

	Monthly income (NTD)	Hourly income (NTD) ^a
Male^b		
15 - 19 years	18,300	103
20 - 24 years	25,680	145
25 - 29 years	33,210	187
30 - 34 years	36,090	203
35 - 39 years	40,470	228
40 - 44 years	43,590	245
45 - 49 years	45,930	259
50 - 54 years	44,280	249
55 - 59 years	43,980	248
60 - 64 years	44,760	252
65 - 69 years	34,740	196
70 & over	0	0
Female^b		
15 - 19 years	16,590	96
20 - 24 years	24,600	143
25 - 29 years	30,420	176
30 - 34 years	32,520	189
35 - 39 years	34,440	200
40 - 44 years	36,000	209
45 - 49 years	36,930	214
50 - 54 years	35,850	208
55 - 59 years	34,830	202
60 - 64 years	34,440	200
65 - 69 years	23,100	134
70 & over	0	0
Caregivers^b	36,510	208

NTD, New Taiwan Dollar, 1 US Dollar = 30 New Taiwan Dollars.

^a Average hourly income = average monthly income / average monthly working hours.

^b Average monthly working hours: male = 177.6 hrs.; female = 172.5 hrs.; caregivers = 175.3 hrs.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1	Out-of-pocket costs and...
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Results: There were...
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5	However, from a patient’s as
Objectives	3	State specific objectives, including any prespecified hypotheses	5	We, therefore, conducted
Methods				
Study design	4	Present key elements of study design early in the paper	5	Study design
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	Ours was a multicentre study ...
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6	<i>Cross-sectional study</i> Sampling
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		Articulate ESRD patients who were...
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6	We examine the differences in OOP costs...
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6	OOP costs included all expenses related...
Bias	9	Describe any efforts to address potential sources of bias	7	Sensitivity analysis
Study size	10	Explain how the study size was arrived at	6	Sampling

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7	The patient interviews...
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7	Frequencies for categorical...
		(b) Describe any methods used to examine subgroups and interactions	NA	
		(c) Explain how missing data were addressed	NA	<i>Cross-sectional study</i> , face by face interviews, no missing data.
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7	Finally, as patient characteristics...
		(e) Describe any sensitivity analyses	7	Sensitivity analysis
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7	A total of 308 HD patients and 246 PD patients...
		(b) Give reasons for non-participation at each stage	NA	
		(c) Consider use of a flow diagram	NA	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7, 15-17	Table 1 and table 2
		(b) Indicate number of participants with missing data for each variable of interest	NA	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA	<i>Cross-sectional study</i>
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8, 18-20	Table 3 and table 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8, 18-20	Table 3 and table 4
		(b) Report category boundaries when continuous variables were categorized	8, 18-20	Table 3 and table 4
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful	NA	

		time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9, 21	Table 5
Discussion				
Key results	18	Summarise key results with reference to study objectives	9	The main results of...
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11	The results of this study have some limitations...
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11	These findings are...
Generalisability	21	Discuss the generalisability (external validity) of the study results	11	To extend the generalisability of...
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12	Funding: This study

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023062.R2
Article Type:	Research
Date Submitted by the Author:	29-Dec-2018
Complete List of Authors:	Tang, Chao-Hsiun ; Taipei Medical University, School of Health Care Administration, College of Management Chen, Hsi-Hsien; Taipei Medical University Hospital, Division of Nephrology, Department of Internal Medicine, Wu, Ming-Ju; Taichung Veterans General Hospital, Division of Nephrology, Department of Internal Medicine Hsu, Bang-Gee ; Buddhist Tzu Chi General Hospital, Division of Nephrology, Department of Internal Medicine Tsai, Jer-Chia ; Kaohsiung Medical University Chung Ho Memorial Hospital, Department of Internal Medicine Kuo, Chi-Cheng; Taipei Medical University, School of Health Care Administration, College of Management Lin, Shih-Pi; Lenity Clinic, Kaohsiung Chen, Tso-Hsiao ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, SUE, YUH-MOU; School of Medicine, College of Medicine, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine,
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Medical management
Keywords:	cost, haemodialysis, out-of-pocket cost, peritoneal dialysis, productivity loss

SCHOLARONE™
Manuscripts

1
2
3
4 **Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis**
5 **from a patient interview survey in Taiwan**

6 **Running title:** Costs of HD and PD in Taiwan

7
8
9 **Authors:**

10 Chao-Hsiun Tang, PhD¹, Hsi-Hsien Chen, MD, PhD², Ming-Ju Wu, MD, PhD³, Bang-Gee Hsu,
11 MD, PhD⁴, Jer-Chia Tsai, MD⁵, Chi-Cheng Kuo, MBA¹, Shih-Pi Lin, MD⁶, Tso-Hsiao Chen,
12 MD, PhD⁷, Yuh-Mou Sue, MD⁷

13
14
15
16 **Affiliations:**

17
18 ¹School of Health Care Administration, College of Management, Taipei Medical University,
19 Taipei, Taiwan

20
21
22 ²Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
23 Medicine and Division of Nephrology, Department of Internal Medicine, Taipei Medical
24 University Hospital, Taipei Medical University, Taipei, Taiwan

25
26
27 ³Division of Nephrology, Department of Internal Medicine, Taichung Veterans General
28 Hospital, Taichung, Taiwan

29
30
31 ⁴Division of Nephrology, Department of Internal Medicine, Buddhist Tzu Chi General
32 Hospital and School of Medicine, Tzu Chi University, Hualien, Taiwan

33
34
35 ⁵Department of Internal Medicine, Kaohsiung Medical University Hospital and Faculty of
36 Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

37
38
39 ⁶Lenity Clinic, Kaohsiung, Taiwan

40
41
42 ⁷Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
43 Medicine and Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital,
44 Taipei Medical University, Taipei, Taiwan

45
46
47
48 **Correspondence:** Yuh-Mou Sue, MD, Division of Nephrology, Department of Internal
49 Medicine, Wan Fang Hospital, Taipei Medical University, 5th Floor, 111 Xing Long Road,
50 Section 3, Taipei 116, Taiwan

51
52
53 E-mail: sueym@tmu.edu.tw; Tel: 886-2-29307930-8103; Fax: 886-2-29302448

ABSTRACT

Objectives: The total medical (economic) costs of haemodialysis (HD) and peritoneal dialysis (PD), including direct medical costs, out-of-pocket (OOP) costs, and productivity losses, have become an important issue. This study aims to compare the direct non-medical costs and indirect medical costs of both modalities in Taiwan.

Design and Setting: This multicentre study included cross-sectional interviews of patients over 20 years old and articulate, who had been continuously receiving long-term HD or PD for more than three months between April 2015 and March 2016. Mann-Whitney U test, Wilcoxon rank sum test, and 1,000 bootstrap procedures with replacement were used for analysis.

Outcome measures: Differences in OOP costs and productivity losses.

Results: There were 308 HD and 246 PD patients available for analysis. HD patients had significantly higher monthly OOP costs than PD patients after bootstrap procedures (NTD 5,912 vs. NTD 5,225, $p < 0.001$; NTD, New Taiwan Dollars; 1 US Dollar = 30 NTD). Compared with PD patients, HD patients had higher monthly productivity losses after bootstrap procedures (NTD 14,150 vs. NTD 11,611, $p < 0.001$), resulting from more time spent seeking outpatient care (HD, 70.4 hours vs. PD, 4.4 hours, $p < 0.001$) and time spent by family caregivers for outpatient care (HD, 66.1 hours vs. PD, 6.1 hours, $p < 0.001$). The total costs per patient-month of HD and PD modalities, including OOP costs and productivity losses were NTD 20,062 and NTD 16,836, respectively.

Conclusions: The HD modality has higher OOP costs and productivity losses than the PD modality in Taiwan.

Keywords: cost, haemodialysis; out-of-pocket cost; peritoneal dialysis; productivity loss

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This multicentre study included cross-sectional interviews of long-term HD and PD patients.
- Previous study seldom assessed the information about out-of-pocket payments and productivity losses collected from patient undergoing HD and PD.
- The difference in the proportion of age groups in HD and PD patients are the major drawback of this study.
- The sample size could not represent the general population of HD and PD patients in Taiwan because the sampled patients were also not randomised

INTRODUCTION

Since March 1995, when Taiwan began implementing the National Health Insurance (NHI) system, the per capita healthcare expenditure has increased annually, especially in the care of ‘end-stage renal disease’ (ESRD) patients. Taiwan has the highest incidence and prevalence rates of ESRD in the world.¹⁻³ By 2017, the cost of dialysis (New Taiwan Dollar, NTD 36.9 billion; 1 US dollar = 30 NTDs in Dec. 2017) accounted for a staggering 5.73% of the total annual NHI expenditure (NTD 644.1 billion).³ Haemodialysis (HD) and peritoneal dialysis (PD) are the two major renal replacement modalities in Taiwan with a similar all-cause mortality rate.⁴⁻⁷ Several studies have provided clear evidence that HD has the higher direct medical costs among the two modalities.⁸⁻¹⁴ NHI administrators implemented several strategies besides applying a blanket budget cap on dialysis expenditure to contain the total costs of dialysis and incentivize the use of PD modality. These efforts included increasing the reimbursements for PD and extending the NHI payment scheme covering the automated PD machine costs. As the proportion of PD usage increases, its prevalence in Taiwan has been gradually increasing, from 6.5% in 2003 to 8.5% in 2007, and up to 9.2% in 2014, similar to the average level within the developed countries.¹⁵⁻¹⁸

ESRD prevalence is increasing with the rise in the number of aging and diabetic nephropathy patients. The total (economic) costs of HD and PD modalities, including direct medical costs, direct non-medical costs, and productivity losses, have become an important issue.¹⁹ Direct medical costs incurred for medical services, such as dialysis costs, physician and nurses’ services, diagnostic tests, and hospitalization costs, are the most common type cited in the nephrologic literature. From a payer’s perspective (e.g., national insurance organizations), these costs are the most important. However, from a patient’s as well as societal perspectives, out-of-pocket (OOP) costs and productivity losses are nominal and meaningful. OOP costs and productivity losses have not been assessed comprehensively in

1
2
3 ESRD patients for two reasons: the methods for collecting these data for the ESRD patients
4
5 are not well established, and retrospective data collection is difficult. Only two studies have
6
7 reported that PD had less OOP costs and productivity losses than HD in Brazil and Singapore,
8
9 but detailed data were not stated.^{12 20} These studies highlighted a significant economic burden
10
11 due to dialysis and a higher direct healthcare costs associated with the use of HD modality;
12
13 however, little information is available about OOP costs, including expenses on caregivers or
14
15 transportation, as well as productivity losses, including job loss, worker replacement, and
16
17 reduced productivity from patients and family. According to the 2016 Annual Report on
18
19 Kidney Disease in Taiwan, HD patients had higher NHI expenses (NTD 70,000 per patient-
20
21 month) than PD patients (NTD 51,000 per patient-month), owing to higher cost of outpatient
22
23 care (HD, NTD 56,000 per patient-month; PD, NTD 43,000 per patient-month) and inpatient
24
25 care (HD, NTD 13,400 per patient-month; PD, NTD 8,200 per patient-month).¹⁵ However,
26
27 the extent to which OOP costs and productivity losses contribute to the overall economic
28
29 burden of HD and PD are yet to be explored in Taiwan. We, therefore, conducted this study
30
31 from a patient's and societal perspectives, using face-to-face interviews to compare OOP
32
33 costs and productivity losses between HD and PD patients in Taiwan.
34
35
36
37
38
39
40

41 **METHODS**

42 **Study Design**

43
44
45 Ours was a multicentre study using cross-sectional interviews with patients over 20
46
47 years old, carried out at the nephrology outpatient clinics of five hospitals and five dialysis
48
49 clinics located in northern, central, southern, and eastern Taiwan between April 2015 and
50
51 March 2016. The Joint Institutional Review Board of Taipei Medical University approved
52
53 this study (No. 201503057). All participants provided informed consent to participate in this
54
55 study. All aspects of the study were performed in accordance with relevant guidelines and
56
57 regulations.
58
59
60

Patient and Public Involvement

No patients were asked for input in the creation of this article.

Sampling

Articulate ESRD patients who were receiving long-term HD or PD continuously for more than three months were chosen. Those aged less than 20 years or unable to communicate were excluded. Patients were recruited and enrolled using a 1:1 male-to-female enrolment design. A total of 581 ESRD patients were screened at the contributing sites, of whom 554 were eligible and enrolled. In total, there were 308 HD patients (156 men, 152 women) and 246 PD patients (124 men, 122 women; 117 automated PD, 129 continuous ambulatory PD) available for analysis.

The patient interviews were performed face by face by well-trained nurses from the site or graduate students from the Taipei Medical University during HD therapy or monthly PD clinic visit. All interviewers had attended prior interviewer training. The patients' baseline characteristics were collected from their medical chart and own response. The patient details collected include sociodemographics, comorbidities, cause of ESRD, and dialysis data (Table 1 and 2). We examine the differences in OOP costs and productivity losses between HD and PD patients. OOP costs included all expenses related to ESRD paid by the patients/family and not reimbursed by the NHI, such as expenses for medicines, medical materials and devices, herbal and alternative medicines, nutritional supplements, transportation costs, and caregiver costs. By using the 'human capital approach',²¹ productivity losses were valued and measured by multiplying the loss of time in hours or days with average hourly/daily wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan (see supplementary Table S1). There were two sources of time loss being evaluated: patients' and caregivers' time spent in seeking care and time spent in operating the dialysis apparatus at home.

Statistical Analysis

The analyses began with a baseline comparison of patients receiving either HD or PD therapy. Frequencies for categorical variables and means with standard deviations or medians with interquartile ranges for continuous variables were calculated. Statistical differences between the HD and PD patients were determined with Chi-square (χ^2) tests, Mann-Whitney U test and Wilcoxon rank sum test as appropriate to analyse the patient interview survey data. Finally, as patient characteristics and costs may differ outside clinical settings and in different conditions, a bootstrap analysis was further performed on OOP costs and productivity losses, by applying 1,000 bootstrap procedures of HD and PD patients with replacement, stratified by age groups. The difference between the groups was significant for the two-sided p -value <0.05 . All the analyses in this study were carried out using the SAS 9.3 software (SAS Institute Inc., Cary, NC, USA).

Sensitivity Analysis

Moreover, the HD and PD patients are a group of patients with a debilitating illness and may receive lower wage rates than the general population resulting in lower productivity losses. To assess the impact of productivity losses on the sum of OOP costs and productivity losses, we first defined the total costs of out-of-pocket costs and productivity losses after bootstrap analysis as Model 1. Then we adjusted the productivity losses for the mean Taiwan unemployment rate (3.82%) during the interview period (between April 2015 and March 2016) and then set the productivity losses with a 20%, 30%, or 40% decrement of wages as different scenarios (Model 2–4) to calculate the total amount of these two costs.²²

RESULTS

A total of 308 HD patients and 246 PD patients were interviewed in the multicentre cross-sectional study. Patient baseline characteristics are shown in Table 1. HD patients were older as more patients were over 70 years old. Diabetes and ischemic heart disease

1
2
3 prevalence was higher and hypertension was lower in HD patients. Hypertension and lupus
4 nephritis had a discernibly different causation of ESRD between the HD and PD patients.
5
6 Marital status, education, and income were not statistically different between the groups. The
7
8 dialysis-related baseline data are reported in Table 2, where the maximum differences were
9
10 found to be the duration of dialysis, haemoglobin, serum albumin, and potassium.
11
12
13

14
15 Table 3 shows the results of the per patient-month OOP costs. There were discernible
16
17 differences between the HD and PD patients in the OOP costs (NTD 5,922 vs. NTD 5,237, p
18 <0.01). The HD patients had significantly lower copayment for outpatient visits, medicine not
19 covered by NHI, and medical equipment, but higher copayment for hospitalizations and
20 transportation than the PD patients. Chinese medication, traditional medicine, and nutritional
21 supplements showed no discernible differences between groups. Another main source of the
22 differences between the HD and PD patients were the transportation costs, owing to more
23 frequent transportation in the former group. However, the results of the mean OOP costs were
24 not consistent in each age group. PD patients had significantly higher OOP costs than the
25 corresponding HD patients in the age groups of 50–59 years old and over 70 years old.
26
27
28
29
30
31
32
33
34
35
36

37
38 Results of the per patient-month productivity losses are reported in Table 4. Compared
39
40 with the PD patients, the HD patients had higher monthly productivity losses (NTD 14,147
41 vs. NTD 11,604, $p <0.01$), resulting from more time spent seeking outpatient care (HD, 70.4
42 ± 6.9 hours vs. PD, 4.4 ± 2.5 hours, $p <0.001$) and time spent by family caregivers for
43 outpatient care (HD, 66.1 ± 51.5 hours vs. PD, 6.1 ± 4.1 hours, $p <0.001$). However, only
44 10.4% and 31.3% of HD and PD patients, respectively, had family caregivers who
45 accompanied them for outpatient care. The productivity losses resulting from time spent
46 operating the dialysis apparatus (49.9 ± 27.8 hours) were only seen in PD patients but not HD
47 patients. After the 1,000 bootstrap procedures, the results of the mean productivity losses
48 remained unchanged in each age group. HD patients had significantly lower productivity
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 losses in the age group over 70 years old because no productivity losses were included
4
5 beyond the age of 70 years.
6

7
8 Table 5 reports the total costs per patient-month, including OOP costs and productivity
9
10 losses. The productivity losses were further adjusted for mean Taiwan unemployment rate
11
12 (3.82%) during the interview survey periods. Models 2–4 show the total costs including OOP
13
14 costs and productivity losses adjusted for unemployment rate with a 20%, 30%, or 40%
15
16 decrement of wages as different scenarios. After considering the productivity losses under
17
18 various scenarios, the differences of total costs between the HD and PD patients slightly
19
20 decreased in Models 2–4. After stratified by age groups, the total costs per patient-month of
21
22 HD patients were higher than those of PD patients except in the age group older than 70 years
23
24 old.
25
26

27
28 Incorporating the NHI-financed medical costs of HD and PD reported in the 2016
29
30 Annual Report on Kidney Disease in Taiwan into the findings in this study ¹⁵, Figure 1 shows
31
32 the per patient-month total costs are NTD 90,062 for HD and NTD 67,836 for PD, to which
33
34 OOP costs contributed 6.6% and 7.7%, and productivity losses 15.7% and 17.1%,
35
36 respectively. For the NTD 22,227 per-patient-month difference in the costs of HD and PD,
37
38 OOP and productivity losses account for 3.1% and 11.4% of the differences, respectively.
39
40
41
42

43 **DISCUSSION**

44
45
46 The main results of this cross-sectional, multicentre interview survey demonstrate that
47
48 total monthly OOP costs and productivity losses of HD (NTD 19,522) were higher than that
49
50 of PD (NTD 16,392) after adjusting for unemployment rate. The OOP costs for the HD
51
52 patients were NTD 687 higher than that for the PD patients, with the greatest difference being
53
54 found in the costs of copayment to hospitalizations and transportation costs. The main
55
56 sources of the differences between HD and PD patients for productivity losses were seeking
57
58 outpatient care and time spent operating the dialysis apparatus. The total economic costs of
59
60

1
2
3 HD (NT 90,062), including NHI expenses, OPP costs and productivity losses, were higher
4
5 than those of PD (NT 67,836), which were most contributed by NHI expenses (NT 19,000,
6
7 85.5%) (Figure 1).
8
9

10 These findings are rarely assessed in previous studies but important for the care of
11
12 ESRD patients because the OOP costs and productivity losses constitute an important, but
13
14 frequently omitted, part of the overall evaluation of economic burden borne by patients and
15
16 their families. Previous studies reported that a significantly higher total NHI-financed
17
18 medical costs were discernible among the HD patients than among the PD patients in several
19
20 countries, including Taiwan, USA, and UK.^{10 15 23} The total costs per patient-month of HD
21
22 and PD patients, including the OOP costs and productivity losses (Table 5, Model 1), were
23
24 NTD 20,063 and NTD 16,836, respectively, with a difference of NTD 3,227 per patient-
25
26 month. From the payer's perspective, the NHI-financed medical costs of PD seems to be a
27
28 better cost-saving modality; similarly, from a patient's and societal perspective, the total costs
29
30 per patient-month of HD were higher owing to higher OOP costs except in the age group
31
32 more than 70 years old (Table 5). Aged ESRD patients often have comorbidities, such as
33
34 diabetes mellitus with retinopathy and poor vision acuity. Considering the necessity of
35
36 caregiver's support to complete the every day's procedures, most patients would not choose
37
38 PD as a favour choice to prevent the OOP cost of caregiver. Compared with HD patients, PD
39
40 patients with diabetes mellitus or age more than 65 years old also had increased death rate.
41
42 All these factors would discourage patients to choosing PD as their renal replacement
43
44 modality.⁵
45
46
47
48
49

50
51 In this study, productivity losses were estimated according to the human capital
52
53 approach using the reduced future gross income, including lower paid or unpaid production
54
55 due to seeking medical care and operating the PD apparatus.²¹ Productivity losses accounted
56
57 for 31.7% of the overall costs in the HD patients, which is similar to 31.8% in the PD
58
59
60

1
2
3 patients. The mean difference of the productivity losses after bootstrap procedures between
4
5 HD and PD patients was NTD 2,539 (Table 4). The results reflected that the productivity
6
7 losses, resulting from the time spent seeking outpatient care and operating the dialysis
8
9 apparatus were significantly lower in the PD than in the HD patients. The productivity losses
10
11 in HD patients decreased gradually in the older age groups and was higher than those of PD
12
13 patients in the same age group (Table 4). Unlike the HD patients, who needed to visit a HD
14
15 centre three times a week, the PD patients could work freely and spent less time in operating
16
17 the dialysis apparatus and had lower productivity losses. When compared to HD, PD is a self-
18
19 care and time-saving modality, which explains the lower productivity losses. In patients with
20
21 chronic kidney disease stage 5 near ESRD, facing with numerous decisions across the
22
23 trajectory of their illness are needed. Using shared decision making approach offers a patient-
24
25 centered method to nudge patients facing health-related decisions, including the choice of
26
27 HD, PD, kidney transplantation or hospice care. The OOP costs and productivity losses have
28
29 significant impact on quality of lives and cost of healthcare delivery. Exploring the detailed
30
31 information will provide evidence based, high-quality decision aids and be able to meet
32
33 patients' informational needs. To extend the generalisability of our findings to other national
34
35 health systems, our result demonstrates that PD modality may appear to be more suitable for
36
37 its markedly lower productivity losses for countries with a younger dialysis patient
38
39 population (less than 70 years old), or with a higher value hourly wage or daily wage. The
40
41 population characteristics, summarized in Table 1, serves as a basis for considering extending
42
43 the results to other populations/medical systems. If the baseline characteristics
44
45 (demographics, clinical need) are similar across populations, the generalizability seems more
46
47 convincing.

48
49 The results of this study confirmed HD modality had higher OOP costs and productivity
50
51 losses than PD modality shown in previous studies.^{12 20} This study also found that
52
53
54
55
56
57
58
59
60

1
2
3 productivity losses contributed 15.2% and 16.5% to the total economic burden of HD and
4
5 PD, respectively, which were higher than 12.4% and 9.8% found in the Brazilian study.²⁰

7 This discrepancy may reflect the difference in healthcare system in Taiwan, where medical
8
9 care is mainly financed by National Health Insurance and in Brazil where patients pay out-of-
10
11 pocket for their medical care.
12

14 The results of this study have some limitations. First, the difference in the proportion of
15
16 age groups in HD and PD patients are the major drawback of this study. From the 2016
17
18 Annual Report on Kidney Disease in Taiwan, the mean ages of HD and PD commencement
19
20 in 2014 were 66.7 and 57.3, respectively, which were older than those of HD and PD patients
21
22 in this cross-sectional study (61.0 and 56.2, respectively, Table 1).¹⁵ Due to this difference, it
23
24 was difficult to obtain sampling of these two groups of patients in the similar age range.
25
26 Therefore, we analysed the results by stratifying into four age groups to compare the
27
28 differences. Second, the results of this study should be interpreted cautiously. The sample
29
30 size could not represent the general population of HD and PD patients in Taiwan because the
31
32 sampled patients were also not randomised, although they were sampled from different parts
33
34 of Taiwan. Third, the impaired productivity or reduced effectiveness at work associated with
35
36 HD or PD were not included in this study, so the productivity losses may thus have led to an
37
38 underestimation.
39
40
41
42
43

44 In this study, we present a patient interview survey in Taiwan to analyse the OOP costs
45
46 and productivity losses for HD and PD patients. From a patient's and societal perspective, the
47
48 HD patients have higher OOP costs and productivity losses than the PD patients in the age
49
50 group less than 70 years old owing to higher productivity losses.
51
52

53
54 **Contributors:** CHT and YMS: study concept and design. HHC, MJW, BGH, JCT, CCK,
55
56 SPL, and THC: acquisition of data. CCK, CHT and YMS: analysis and interpretation. CHT
57
58 and YMS: drafted the manuscript. HHC, MJW, BGH, JCT, SPL, and THC: critical revision
59
60

1
2
3 of the manuscript for important intellectual content. All authors: approved the final paper.
4
5 CHT and YMS are fully responsible for the paper.
6
7

8 **Acknowledgement:** We thank doctors Ming-Kuhn Ruaan, Su-Chen Lin, Jui-Yuan Hung, and
9
10 Wen-Sheng Ko for their assistance in collecting clinical data.
11
12

13 **Funding:** This study was supported by grants from Wan Fang Hospital, Taipei Medical
14
15 University (105TMU-WFH-05).
16
17

18 **Competing interests:** None declared.
19

20 **Data sharing statement:** All relevant data have been included in the paper.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. *Nephrol Dial Transplant* 2008;23(12):3977-82.
2. United States Renal Data System. USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2014.
3. National Health Insurance Administration, Ministry of Health and Welfare. [Available from: https://www.nhi.gov.tw/Content_List.aspx?n=CF2EDC7144006740&topn=D39E2B72B0BDFA15 accessed June 15 2017.
4. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med* 2011;171(2):110-8.
5. Chang YK, Hsu CC, Hwang SJ, et al. A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. *Medicine (Baltimore)* 2012;91(3):144-51.
6. Karopadi AN, Mason G, Rettore E, et al. The role of economies of scale in the cost of dialysis across the world: a macroeconomic perspective. *Nephrol Dial Transplant* 2014;29(4):885-92.
7. Kao TW, Chang YY, Chen PC, et al. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. *Perit Dial Int* 2013;33(6):671-8.
8. Roggeri A, Roggeri DP, Zocchetti C, et al. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. *J Nephrol* 2017;30(2):263-69.
9. Salonen T, Reina T, Oksa H, et al. Cost analysis of renal replacement therapies in Finland. *Am J Kidney Dis* 2003;42(6):1228-38.
10. Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting--a multicentre study. *Nephrol Dial Transplant* 2008;23(6):1982-9.
11. Hornberger J, Hirth RA. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. *Am J Kidney Dis* 2012;60(2):280-7.
12. Yang F, Lau T, Luo N. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. *Nephrology (Carlton)* 2016;21(8):669-77.
13. Chang YT, Hwang JS, Hung SY, et al. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score. *Sci Rep* 2016;6:30266.

14. Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of renal replacement therapy in Austria. *Nephrol Dial Transplant* 2011;26(9):2988-95.
15. 2016 Annual Report on Kidney Disease in Taiwan. Taipei, Taiwan. 2017.
16. Wu MS, Wu IW, Shih CP, et al. Establishing a platform for battling end-stage renal disease and continuing quality improvement in dialysis therapy in Taiwan-Taiwan Renal Registry Data System (TWRDS). *Acta Nephrologica* 2011;25(3):148-53.
17. Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. *J Am Soc Nephrol* 2012;23(3):533-44.
18. Li PK, Chow KM, Van de Luitgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. *Nat Rev Nephrol* 2017;13(2):90-103.
19. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. *JAMA* 1989;262(20):2879-86.
20. de Abreu MM, Walker DR, Sesso RC, et al. A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil. *Perit Dial Int* 2013;33(3):304-15.
21. Liljas B. How to calculate indirect costs in economic evaluations. *Pharmacoeconomics* 1998;13(1 Pt 1):1-7.
22. Unemployment rate. : National Statistics, R.O.C. (Taiwan). 2016 [Available from: <https://www.stat.gov.tw/point.asp?index=3> accessed December 31 2016].
23. Bruns FJ, Seddon P, Saul M, et al. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. *J Am Soc Nephrol* 1998;9(5):884-90.

Table 1. Patient characteristics of the interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Male gender	156 (50.7)	124 (50.4)	0.96
Age (y)	61.0 [12.7]	56.2 [13.9]	<0.01
<50	68 (22.1)	71 (28.9)	
50-59	79 (25.7)	67 (27.2)	
60-69	76 (24.7)	70 (28.5)	
≥70	85 (27.6)	38 (15.5)	
Comorbidities			
Diabetes mellitus	130 (42.2)	74 (30.1)	<0.01
Hypertension	204 (66.2)	193 (78.5)	<0.01
Cancer	17 (5.5)	7 (2.9)	0.13
Chronic obstructive pulmonary disease	5 (1.6)	2 (0.81)	0.40
Cirrhosis of liver	5 (1.6)	3 (1.2)	0.91
Dementia	3 (1.0)	4 (1.6)	0.50
Cerebrovascular disease	8 (2.6)	6 (2.4)	0.91
Peripheral vascular disease	15 (4.9)	8 (3.25)	0.34
Cardiac dysrhythmia	36 (11.7)	20 (8.1)	0.17
Ischemic heart disease	22 (7.1)	6 (2.4)	0.01
Myocardial infarction	11 (3.6)	8 (3.3)	0.84
Chronic heart failure	13 (4.2)	9 (3.7)	0.74
Cause of end-stage renal disease			
Chronic glomerulonephritis	111 (36.0)	82 (33.3)	0.44
Diabetes mellitus	118 (38.3)	71 (28.9)	0.11
Hypertension	108 (35.1)	52 (21.1)	0.02
Hereditary polycystic kidney disease	10 (3.3)	6 (2.4)	0.83
Chronic tubulointerstitial nephritis	5 (1.6)	7 (2.9)	0.19
Lupus nephritis	4 (1.3)	11 (4.5)	<0.01
Others	51 (16.6)	43 (17.5)	0.21
Marital status			0.18
Singled	45 (14.6)	52 (21.1)	
Married	210 (68.2)	159 (64.6)	
Divorced	25 (8.1)	15 (6.2)	
Widowed	28 (9.1)	20 (8.1)	
Education years			0.09
Below primary school	26 (8.4)	15 (6.1)	
Primary school	77 (25.0)	51 (20.7)	
Junior high school	50 (16.2)	31 (12.6)	

1				
2				
3	Senior high school	88 (28.6)	69 (28.1)	
4	College	59 (19.2)	66 (26.8)	
5	Above college	8 (2.6)	14 (5.7)	
6				
7				
8	Family income (NTD)			0.17
9	<30,000	93 (30.2)	80 (32.5)	
10	30,000-49,999	99 (32.1)	61 (24.8)	
11	50,000-69,999	61 (19.8)	46 (18.7)	
12	70,000-99,999	31 (10.1)	25 (10.1)	
13	100,000-149,999	9 (2.9)	23 (9.4)	
14	150,000-199,999	6 (2.0)	8 (3.3)	
15	≥200,000	9 (2.9)	3 (1.2)	
16				
17				
18				
19				

20 Data were number (%) or mean [standard deviation]. HD: haemodialysis; NTD: New Taiwan Dollar (1 US
 21 Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis.
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

Table 2. Dialysis related baseline data of interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Duration of dialysis (month)	63 (26-135)	37 (16-63)	<0.001
Systolic blood pressure (mmHg)	141.8 [24.7]	141.0 [23.2]	0.58
Diastolic blood pressure (mmHg)	76.1 [12.6]	82.3 [14.9]	<0.001
Heart rate (beats/min)	77.5 [10.3]	81.8 [15.1]	<0.01
Serum albumin (g/dL)	4.0 [0.4]	3.8 [0.7]	<0.001
Serum potassium (mmol/L)	4.8 [0.8]	4.0 [0.6]	<0.001
Standard Kt/V (HD) or Kt/V (PD)	2.39 [0.32]	1.97 [0.31]	<0.001
Urea reduction ratio	73.9 [6.2]	— —	—
Weekly creatinine clearance (ml/min)	— —	60.1 [12.5]	—
Normalized protein nitrogen appearance	— —	1.0 [0.2]	—
Hemoglobin (g/dL)	10.5 [1.5]	10.1 [1.5]	<0.01
Body mass index	23.7 [4.5]	23.9 [3.9]	0.22

Data were median (interquartile range) or mean [standard deviation]. HD: haemodialysis; PD: peritoneal dialysis.

Table 3. Per patient-month out-of-pocket costs of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	5,922 (12,963)	1,794 (488-4,784)	5,237 (7,571)	2,492 (1,018-5,598)	<0.01
Copayment to outpatient care	103 (377)	0 (0-120)	361 (696)	120 (50-400)	<0.001
Copayment to inpatient care	2,209 (11,093)	0 (0-0)	995 (2,163)	0 (0-1,240)	<0.001
Medicine not covered by NHI	591 (1,832)	0 (0-417)	995 (1,911)	125 (0-1,078)	<0.001
Medical equipment	110 (448)	0 (0-0)	439 (726)	208 (0-675)	<0.001
Chinese medication	27 (175)	0 (0-0)	183 (2,153)	0 (0-0)	0.53
Traditional medicine	38 (257)	0 (0-0)	51 (550)	0 (0-0)	0.35
Nutritional supplements	241 (749)	0 (0-0)	542 (2,398)	0 (0-106)	0.26
Transportation costs	1,028 (1,707)	293 (0-1,495)	191 (229)	143 (16-293)	<0.001
Caregiver costs	1,574 (5,453)	0 (0-0)	1,480 (5,309)	0 (0-0)	0.90
Stratified by age groups					
Age <50 (y)	3,766 (5,785)		2,771 (3,150)		0.32
Age 50-59 (y)	4,902 (14,857)		5,824 (7,484)		<0.001
Age 60-69 (y)	7,337 (14,140)		4,091 (6,072)		0.68
Age ≥70 (y)	7,330 (13,980)		10,922 (12,006)		<0.01
After bootstrap procedures					
Total	5,912 (819)		5,225 (485)		<0.001
Stratified by age groups					
Age <50 (y)	3,787 (686)		2,776 (375)		<0.001
Age 50-59 (y)	4,814 (1,678)		5,827 (870)		<0.001
Age 60-69 (y)	7,270 (1,559)		4,111 (701)		<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Age \geq 70 (y)	7,348 (1,521)	10,932 (1,855)	<0.001
-------------------	---------------	----------------	--------

HD: haemodialysis; IQR: interquartile range; NHI: National health Insurance; NTD, New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

For peer review only

Table 4. Per patient-month productivity losses of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	14,147 (10,746)	13,936 (6,961-20,921)	11,604 (7,949)	10,576 (5,315-16,764)	<0.01
Time spent operating dialysis apparatus	— —	— —	8,655 (6,785)	7,450 (3,138-12,700)	
Seeking outpatient care from patients	11,307 (8,007)	12,874 (0-17,567)	774 (591)	798 (399-1,008)	<0.001
Seeking outpatient care from caregivers	1,608 (5,793)	0 (0-0)	400 (759)	0 (0-833)	<0.001
Seeking inpatient care from patients	799 (1,683)	0 (0-0)	1,037 (1,482)	0 (0-2,918)	0.01
Seeking inpatient care from caregivers	433 (1,251)	0 (0-0)	739 (1,290)	0 (0-733)	<0.001
Stratified by age groups					
Age <50 (y)	19,419 (5,888)		13,177 (7,000)		<0.001
Age 50-59 (y)	19,276 (10,606)		14,424 (7,579)		<0.01
Age 60-69 (y)	17,253 (7,901)		12,826 (6,789)		<0.001
Age ≥70 (y)	2,386 (6,184)		1,207 (1,621)		<0.01
After bootstrap procedures					
Total	14,150 (626)		11,611 (510)		<0.001
Stratified by age groups					
Age <50 (y)	19,381 (715)		13,289 (840)		<0.001
Age 50-59 (y)	19,272 (1,162)		14,415 (878)		<0.001
Age 60-69 (y)	17,212 (857)		12,823 (802)		<0.001
Age ≥70 (y)	2,403 (645)		1,206 (255)		<0.001

HD: haemodialysis; IQR: interquartile range; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

Table 5. Total costs of out-of-pocket costs and productivity losses per patient-month of HD and PD patients after bootstrap analysis (in NTD).

Variables	HD	PD	Difference
(1) Out-of-pocket costs	5,912	5,225	687
Stratified by age groups			
Age <50 (y)	3,787	2,776	1,011
Age 50-59 (y)	4,814	5,827	-1,013
Age 60-69 (y)	7,270	4,111	3,159
Age ≥70 (y)	7,348	10,932	-3,584
(2) Productivity losses	14,150	11,611	2,540
Stratified by age groups			
Age <50 (y)	19,381	13,289	6,093
Age 50-59 (y)	19,272	14,415	4,858
Age 60-69 (y)	17,213	12,823	4,390
Age ≥70 (y)	2,403	1,206	1,197
(3) Total costs			
Model 1 = (1) + (2)	20,062	16,836	3,227
Stratified by age groups			
Age <50 (y)	23,168	16,065	7,103
Age 50-59 (y)	24,086	20,242	3,844
Age 60-69 (y)	24,483	16,934	7,549
Age ≥70 (y)	9,751	12,138	-2,387
Model 2 = (1) + (2) x 20% decrement in wages x (1-0.0382)^a	16,800	14,159	2,641
Model 3 = (1) + (2) x 30% decrement in wages x (1-0.0382)^a	15,439	13,042	2,397
Model 4 = (1) + (2) x 40% decrement in wages x (1-0.0382)^a	14,078	11,925	2,153


HD: haemodialysis; PD: peritoneal dialysis; NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars).

^a Adjusted for mean Taiwan unemployment rate (3.82%) between April 2015 and March 2016.

Figure Legends

Figure 1. Distribution of NHI-financed medical cost¹⁵, out-of-pocket costs, and productivity losses, in HD and PD modalities, and their differences. NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); HD: haemodialysis; PD: peritoneal dialysis.

For peer review only



221x150mm (300 x 300 DPI)

Supplementary Online Content

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Chao-Hsiun Tang, Hsi-Hsien Chen, Ming-Ju Wu, Bang-Gee Hsu, Jer-Chia Tsai, Chi-Cheng Kuo, Shih-Pi Lin, Tso-Hsiao Chen, Yuh-Mou Sue

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

	Monthly income (NTD)	Hourly income (NTD) ^a
Male^b		
15 - 19 years	18,300	103
20 - 24 years	25,680	145
25 - 29 years	33,210	187
30 - 34 years	36,090	203
35 - 39 years	40,470	228
40 - 44 years	43,590	245
45 - 49 years	45,930	259
50 - 54 years	44,280	249
55 - 59 years	43,980	248
60 - 64 years	44,760	252
65 - 69 years	34,740	196
70 & over	0	0
Female^b		
15 - 19 years	16,590	96
20 - 24 years	24,600	143
25 - 29 years	30,420	176
30 - 34 years	32,520	189
35 - 39 years	34,440	200
40 - 44 years	36,000	209
45 - 49 years	36,930	214
50 - 54 years	35,850	208
55 - 59 years	34,830	202
60 - 64 years	34,440	200
65 - 69 years	23,100	134
70 & over	0	0
Caregivers^b		
	36,510	208

NTD, New Taiwan Dollar, 1 US Dollar = 30 New Taiwan Dollars.

^a Average hourly income = average monthly income / average monthly working hours.

^b Average monthly working hours: male = 177.6 hrs.; female = 172.5 hrs.; caregivers = 175.3 hrs.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1	Out-of-pocket costs and...
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Results: There were...
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5	However, from a patient’s as
Objectives	3	State specific objectives, including any prespecified hypotheses	5	We, therefore, conducted
Methods				
Study design	4	Present key elements of study design early in the paper	5	Study design
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	Ours was a multicentre study ...
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6	<i>Cross-sectional study</i> Sampling
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		Articulate ESRD patients who were...
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6	We examine the differences in OOP costs...
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6	OOP costs included all expenses related...
Bias	9	Describe any efforts to address potential sources of bias	7	Sensitivity analysis
Study size	10	Explain how the study size was arrived at	6	Sampling

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7	The patient interviews...
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7	Frequencies for categorical...
		(b) Describe any methods used to examine subgroups and interactions	NA	
		(c) Explain how missing data were addressed	NA	<i>Cross-sectional study</i> , face by face interviews, no missing data.
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7	Finally, as patient characteristics...
		(e) Describe any sensitivity analyses	7	Sensitivity analysis
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7	A total of 308 HD patients and 246 PD patients...
		(b) Give reasons for non-participation at each stage	NA	
		(c) Consider use of a flow diagram	NA	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7, 15-17	Table 1 and table 2
		(b) Indicate number of participants with missing data for each variable of interest	NA	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA	<i>Cross-sectional study</i>
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8, 18-20	Table 3 and table 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8, 18-20	Table 3 and table 4
		(b) Report category boundaries when continuous variables were categorized	8, 18-20	Table 3 and table 4
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful	NA	

		time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9, 21	Table 5
Discussion				
Key results	18	Summarise key results with reference to study objectives	9	The main results of...
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11	The results of this study have some limitations...
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11	These findings are...
Generalisability	21	Discuss the generalisability (external validity) of the study results	11	To extend the generalisability of...
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12	Funding: This study

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023062.R3
Article Type:	Research
Date Submitted by the Author:	06-Feb-2019
Complete List of Authors:	Tang, Chao-Hsiun ; Taipei Medical University, School of Health Care Administration, College of Management Chen, Hsi-Hsien; Taipei Medical University Hospital, Division of Nephrology, Department of Internal Medicine, Wu, Ming-Ju; Taichung Veterans General Hospital, Division of Nephrology, Department of Internal Medicine Hsu, Bang-Gee ; Buddhist Tzu Chi General Hospital, Division of Nephrology, Department of Internal Medicine Tsai, Jer-Chia ; Kaohsiung Medical University Chung Ho Memorial Hospital, Department of Internal Medicine Kuo, Chi-Cheng; Taipei Medical University, School of Health Care Administration, College of Management Lin, Shih-Pi; Lenity Clinic, Kaohsiung Chen, Tso-Hsiao ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, SUE, YUH-MOU; School of Medicine, College of Medicine, Taipei Medical University, Division of Nephrology, Department of Internal Medicine, ; Wan Fang Hospital, Taipei Medical University, Division of Nephrology, Department of Internal Medicine,
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Medical management, Health economics
Keywords:	cost, haemodialysis, out-of-pocket cost, peritoneal dialysis, productivity loss

SCHOLARONE™
Manuscripts

1
2
3
4 **Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis**
5 **from a patient interview survey in Taiwan**

6 **Running title:** Costs of HD and PD in Taiwan

7
8
9 **Authors:**

10 Chao-Hsiun Tang, PhD¹, Hsi-Hsien Chen, MD, PhD², Ming-Ju Wu, MD, PhD³, Bang-Gee Hsu,
11 MD, PhD⁴, Jer-Chia Tsai, MD⁵, Chi-Cheng Kuo, MBA¹, Shih-Pi Lin, MD⁶, Tso-Hsiao Chen,
12 MD, PhD⁷, Yuh-Mou Sue, MD⁷

13
14
15
16 **Affiliations:**

17
18 ¹School of Health Care Administration, College of Management, Taipei Medical University,
19 Taipei, Taiwan

20
21
22 ²Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
23 Medicine and Division of Nephrology, Department of Internal Medicine, Taipei Medical
24 University Hospital, Taipei Medical University, Taipei, Taiwan

25
26
27 ³Division of Nephrology, Department of Internal Medicine, Taichung Veterans General
28 Hospital, Taichung, Taiwan

29
30
31 ⁴Division of Nephrology, Department of Internal Medicine, Buddhist Tzu Chi General
32 Hospital and School of Medicine, Tzu Chi University, Hualien, Taiwan

33
34
35 ⁵Department of Internal Medicine, Kaohsiung Medical University Hospital and Faculty of
36 Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

37
38
39 ⁶Lenity Clinic, Kaohsiung, Taiwan

40
41
42 ⁷Division of Nephrology, Department of Internal Medicine, School of Medicine, College of
43 Medicine and Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital,
44 Taipei Medical University, Taipei, Taiwan

45
46
47 **Correspondence:** Yuh-Mou Sue, MD, Division of Nephrology, Department of Internal
48 Medicine, Wan Fang Hospital, Taipei Medical University, 5th Floor, 111 Xing Long Road,
49 Section 3, Taipei 116, Taiwan

50
51
52 E-mail: sueym@tmu.edu.tw; Tel: 886-2-29307930-8103; Fax: 886-2-29302448

ABSTRACT

Objectives: The total medical (economic) costs of haemodialysis (HD) and peritoneal dialysis (PD), including direct medical costs, out-of-pocket (OOP) costs, and productivity losses, have become an important issue. This study aims to compare the direct non-medical costs and indirect medical costs of both modalities in Taiwan.

Design and Setting: This multicentre study included cross-sectional interviews of patients over 20 years old and articulate, who had been continuously receiving long-term HD or PD for more than three months between April 2015 and March 2016. Mann-Whitney U test, Wilcoxon rank sum test, and 1,000 bootstrap procedures with replacement were used for analysis.

Outcome measures: Differences in OOP costs and productivity losses.

Results: There were 308 HD and 246 PD patients available for analysis. HD patients had significantly higher monthly OOP costs than PD patients after bootstrap procedures (NTD 5,912 vs. NTD 5,225, $p < 0.001$; NTD, New Taiwan Dollars; 1 US Dollar = 30 NTD). Compared with PD patients, HD patients had higher monthly productivity losses after bootstrap procedures (NTD 14,150 vs. NTD 11,611, $p < 0.001$), resulting from more time spent seeking outpatient care (HD, 70.4 hours vs. PD, 4.4 hours, $p < 0.001$) and time spent by family caregivers for outpatient care (HD, 66.1 hours vs. PD, 6.1 hours, $p < 0.001$). The total costs per patient-month of HD and PD modalities, including OOP costs and productivity losses were NTD 20,062 and NTD 16,836, respectively.

Conclusions: The HD modality has higher OOP costs and productivity losses than the PD modality in Taiwan.

Keywords: cost, haemodialysis; out-of-pocket cost; peritoneal dialysis; productivity loss

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This multicentre study included cross-sectional interviews of long-term HD and PD patients.
- Previous study seldom assessed the information about out-of-pocket payments and productivity losses collected from patient undergoing HD and PD.
- The difference in the proportion of age groups in HD and PD patients are the major drawback of this study.
- The sample size could not represent the general population of HD and PD patients in Taiwan because the sampled patients were also not randomised.
- The 12-month recall period of healthcare utilization in this study could make sure all out-of-pocket information in the previous year captured in the answer but possibly caused a recall bias.

INTRODUCTION

Since March 1995, when Taiwan began implementing the National Health Insurance (NHI) system, the per capita healthcare expenditure has increased annually, especially in the care of ‘end-stage renal disease’ (ESRD) patients. Taiwan has the highest incidence and prevalence rates of ESRD in the world.¹⁻³ By 2017, the cost of dialysis (New Taiwan Dollar, NTD 36.9 billion; 1 US dollar = 30 NTDs in Dec. 2017) accounted for a staggering 5.73% of the total annual NHI expenditure (NTD 644.1 billion).³ Haemodialysis (HD) and peritoneal dialysis (PD) are the two major renal replacement modalities in Taiwan with a similar all-cause mortality rate.⁴⁻⁷ Several studies have provided clear evidence that HD has the higher direct medical costs among the two modalities.⁸⁻¹⁴ NHI administrators implemented several strategies besides applying a blanket budget cap on dialysis expenditure to contain the total costs of dialysis and incentivize the use of PD modality. These efforts included increasing the reimbursements for PD and extending the NHI payment scheme covering the automated PD machine costs. As the proportion of PD usage increases, its prevalence in Taiwan has been gradually increasing, from 6.5% in 2003 to 8.5% in 2007, and up to 9.2% in 2014, similar to the average level within the developed countries.¹⁵⁻¹⁸

ESRD prevalence is increasing with the rise in the number of aging and diabetic nephropathy patients. The total (economic) costs of HD and PD modalities, including direct medical costs, direct non-medical costs, and productivity losses, have become an important issue.¹⁹ Direct medical costs incurred for medical services, such as dialysis costs, physician and nurses’ services, diagnostic tests, and hospitalization costs, are the most common type cited in the nephrologic literature. From a payer’s perspective (e.g., national insurance organizations), these costs are the most important. However, from a patient’s as well as societal perspectives, out-of-pocket (OOP) costs and productivity losses are nominal and meaningful. OOP costs and productivity losses have not been assessed comprehensively in

1
2
3 ESRD patients for two reasons: the methods for collecting these data for the ESRD patients
4
5 are not well established, and retrospective data collection is difficult. Only two studies have
6
7 reported that PD had less OOP costs and productivity losses than HD in Brazil and Singapore,
8
9 but detailed data were not stated.^{12 20} These studies highlighted a significant economic burden
10
11 due to dialysis and a higher direct healthcare costs associated with the use of HD modality;
12
13 however, little information is available about OOP costs, including expenses on caregivers or
14
15 transportation, as well as productivity losses, including job loss, worker replacement, and
16
17 reduced productivity from patients and family. According to the 2016 Annual Report on
18
19 Kidney Disease in Taiwan, HD patients had higher NHI expenses (NTD 70,000 per patient-
20
21 month) than PD patients (NTD 51,000 per patient-month), owing to higher cost of outpatient
22
23 care (HD, NTD 56,000 per patient-month; PD, NTD 43,000 per patient-month) and inpatient
24
25 care (HD, NTD 13,400 per patient-month; PD, NTD 8,200 per patient-month).¹⁵ However,
26
27 the extent to which OOP costs and productivity losses contribute to the overall economic
28
29 burden of HD and PD are yet to be explored in Taiwan. We, therefore, conducted this study
30
31 from a patient's and societal perspectives, using face-to-face interviews to compare OOP
32
33 costs and productivity losses between HD and PD patients in Taiwan.
34
35
36
37
38
39
40

41 **METHODS**

42 **Study Design**

43
44 Ours was a multicentre study using cross-sectional interviews with patients over 20
45
46 years old, carried out at the nephrology outpatient clinics of five hospitals and five dialysis
47
48 clinics located in northern, central, southern, and eastern Taiwan between April 2015 and
49
50 March 2016. The Joint Institutional Review Board of Taipei Medical University approved
51
52 this study (No. 201503057). All participants provided informed consent to participate in this
53
54 study. All aspects of the study were performed in accordance with relevant guidelines and
55
56 regulations.
57
58
59
60

Patient and Public Involvement

No patients were asked for input in the creation of this article.

Sampling

Articulate ESRD patients who were receiving long-term HD or PD continuously for more than three months were chosen. Those aged less than 20 years or unable to communicate were excluded. Patients were recruited and enrolled using a 1:1 male-to-female enrolment design. A total of 581 ESRD patients were screened at the contributing sites, of whom 554 were eligible and enrolled. In total, there were 308 HD patients (156 men, 152 women) and 246 PD patients (124 men, 122 women; 117 automated PD, 129 continuous ambulatory PD) available for analysis.

The patient interviews were performed face by face by well-trained nurses from the site or graduate students from the Taipei Medical University during HD therapy or monthly PD clinic visit. All interviewers had attended prior interviewer training. The patients' baseline characteristics were collected from their medical chart and own response. The patient details collected include sociodemographics, comorbidities, cause of ESRD, and dialysis data (Table 1 and 2). We examine the differences in OOP costs and productivity losses between HD and PD patients. OOP costs included all expenses related to ESRD paid by the patients/family and not reimbursed by the NHI, such as expenses for medicines, medical materials and devices, herbal and alternative medicines, nutritional supplements, transportation costs, and caregiver costs. By using the 'human capital approach',²¹ productivity losses were valued and measured by multiplying the loss of time in hours or days with average hourly/daily wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan (see supplementary Table S1). There were two sources of time loss being evaluated: patients' and caregivers' time spent in seeking care and time spent in operating the dialysis apparatus at home.

Statistical Analysis

The analyses began with a baseline comparison of patients receiving either HD or PD therapy. Frequencies for categorical variables and means with standard deviations or medians with interquartile ranges for continuous variables were calculated. Statistical differences between the HD and PD patients were determined with Chi-square (χ^2) tests, Mann-Whitney U test and Wilcoxon rank sum test as appropriate to analyse the patient interview survey data. Finally, as patient characteristics and costs may differ outside clinical settings and in different conditions, a bootstrap analysis was further performed on OOP costs and productivity losses, by applying 1,000 bootstrap procedures of HD and PD patients with replacement, stratified by age groups. The difference between the groups was significant for the two-sided p -value <0.05 . All the analyses in this study were carried out using the SAS 9.3 software (SAS Institute Inc., Cary, NC, USA).

Sensitivity Analysis

Moreover, the HD and PD patients are a group of patients with a debilitating illness and may receive lower wage rates than the general population resulting in lower productivity losses. To assess the impact of productivity losses on the sum of OOP costs and productivity losses, we first defined the total costs of out-of-pocket costs and productivity losses after bootstrap analysis as Model 1. Then we adjusted the productivity losses for the mean Taiwan unemployment rate (3.82%) during the interview period (between April 2015 and March 2016) and then set the productivity losses with a 20%, 30%, or 40% decrement of wages as different scenarios (Model 2–4) to calculate the total amount of these two costs.²²

RESULTS

A total of 308 HD patients and 246 PD patients were interviewed in the multicentre cross-sectional study. Patient baseline characteristics are shown in Table 1. HD patients were older as more patients were over 70 years old. Diabetes and ischemic heart disease

1
2
3 prevalence was higher and hypertension was lower in HD patients. Hypertension and lupus
4 nephritis had a discernibly different causation of ESRD between the HD and PD patients.
5
6 Marital status, education, and income were not statistically different between the groups. The
7
8 dialysis-related baseline data are reported in Table 2, where the maximum differences were
9
10 found to be the duration of dialysis, haemoglobin, serum albumin, and potassium.
11
12
13

14
15 Table 3 shows the results of the per patient-month OOP costs. There were discernible
16
17 differences between the HD and PD patients in the OOP costs (NTD 5,922 vs. NTD 5,237, p
18
19 <0.01). The HD patients had significantly lower copayment for outpatient visits, medicine not
20
21 covered by NHI, and medical equipment, but higher copayment for hospitalizations and
22
23 transportation than the PD patients. Chinese medication, traditional medicine, and nutritional
24
25 supplements showed no discernible differences between groups. Another main source of the
26
27 differences between the HD and PD patients were the transportation costs, owing to more
28
29 frequent transportation in the former group. However, the results of the mean OOP costs were
30
31 not consistent in each age group. PD patients had significantly higher OOP costs than the
32
33 corresponding HD patients in the age groups of 50–59 years old and over 70 years old.
34
35
36

37
38 Results of the per patient-month productivity losses are reported in Table 4. Compared
39
40 with the PD patients, the HD patients had higher monthly productivity losses (NTD 14,147
41
42 vs. NTD 11,604, $p <0.01$), resulting from more time spent seeking outpatient care (HD, 70.4
43
44 ± 6.9 hours vs. PD, 4.4 ± 2.5 hours, $p <0.001$) and time spent by family caregivers for
45
46 outpatient care (HD, 66.1 ± 51.5 hours vs. PD, 6.1 ± 4.1 hours, $p <0.001$). However, only
47
48 10.4% and 31.3% of HD and PD patients, respectively, had family caregivers who
49
50 accompanied them for outpatient care. The productivity losses resulting from time spent
51
52 operating the dialysis apparatus (49.9 ± 27.8 hours) were only seen in PD patients but not HD
53
54 patients. After the 1,000 bootstrap procedures, the results of the mean productivity losses
55
56 remained unchanged in each age group. HD patients had significantly lower productivity
57
58
59
60

1
2
3 losses in the age group over 70 years old because no productivity losses were included
4
5 beyond the age of 70 years.
6

7
8 Table 5 reports the total costs per patient-month, including OOP costs and productivity
9
10 losses. The productivity losses were further adjusted for mean Taiwan unemployment rate
11
12 (3.82%) during the interview survey periods. Models 2–4 show the total costs including OOP
13
14 costs and productivity losses adjusted for unemployment rate with a 20%, 30%, or 40%
15
16 decrement of wages as different scenarios. After considering the productivity losses under
17
18 various scenarios, the differences of total costs between the HD and PD patients slightly
19
20 decreased in Models 2–4. After stratified by age groups, the total costs per patient-month of
21
22 HD patients were higher than those of PD patients except in the age group older than 70 years
23
24 old.
25
26

27
28 Incorporating the NHI-financed medical costs of HD and PD reported in the 2016
29
30 Annual Report on Kidney Disease in Taiwan into the findings in this study ¹⁵, Figure 1 shows
31
32 the per patient-month total costs are NTD 90,062 for HD and NTD 67,836 for PD, to which
33
34 OOP costs contributed 6.6% and 7.7%, and productivity losses 15.7% and 17.1%,
35
36 respectively. For the NTD 22,227 per-patient-month difference in the costs of HD and PD,
37
38 OOP and productivity losses account for 3.1% and 11.4% of the differences, respectively.
39
40
41

42 43 44 **DISCUSSION**

45
46 The main results of this cross-sectional, multicentre interview survey demonstrate that
47
48 total monthly OOP costs and productivity losses of HD (NTD 19,522) were higher than that
49
50 of PD (NTD 16,392) after adjusting for unemployment rate. The OOP costs for the HD
51
52 patients were NTD 687 higher than that for the PD patients, with the greatest difference being
53
54 found in the costs of copayment to hospitalizations and transportation costs. The main
55
56 sources of the differences between HD and PD patients for productivity losses were seeking
57
58 outpatient care and time spent operating the dialysis apparatus. The total economic costs of
59
60

1
2
3 HD (NT 90,062), including NHI expenses, OPP costs and productivity losses, were higher
4
5 than those of PD (NT 67,836), which were most contributed by NHI expenses (NT 19,000,
6
7 85.5%) (Figure 1).
8
9

10 These findings are rarely assessed in previous studies but important for the care of
11
12 ESRD patients because the OOP costs and productivity losses constitute an important, but
13
14 frequently omitted, part of the overall evaluation of economic burden borne by patients and
15
16 their families. Previous studies reported that a significantly higher total NHI-financed
17
18 medical costs were discernible among the HD patients than among the PD patients in several
19
20 countries, including Taiwan, USA, and UK.^{10 15 23} The total costs per patient-month of HD
21
22 and PD patients, including the OOP costs and productivity losses (Table 5, Model 1), were
23
24 NTD 20,063 and NTD 16,836, respectively, with a difference of NTD 3,227 per patient-
25
26 month. From the payer's perspective, the NHI-financed medical costs of PD seems to be a
27
28 better cost-saving modality; similarly, from a patient's and societal perspective, the total costs
29
30 per patient-month of HD were higher owing to higher OOP costs except in the age group
31
32 more than 70 years old (Table 5). Aged ESRD patients often have comorbidities, such as
33
34 diabetes mellitus with retinopathy and poor vision acuity. Considering the necessity of
35
36 caregiver's support to complete the every day's procedures, most patients would not choose
37
38 PD as a favour choice to prevent the OOP cost of caregiver. Compared with HD patients, PD
39
40 patients with diabetes mellitus or age more than 65 years old also had increased death rate.
41
42 All these factors would discourage patients to choosing PD as their renal replacement
43
44 modality.⁵
45
46
47
48
49

50
51 In this study, productivity losses were estimated according to the human capital
52
53 approach using the reduced future gross income, including lower paid or unpaid production
54
55 due to seeking medical care and operating the PD apparatus.²¹ Productivity losses accounted
56
57 for 31.7% of the overall costs in the HD patients, which is similar to 31.8% in the PD
58
59
60

1
2
3 patients. The mean difference of the productivity losses after bootstrap procedures between
4
5 HD and PD patients was NTD 2,539 (Table 4). The results reflected that the productivity
6
7 losses, resulting from the time spent seeking outpatient care and operating the dialysis
8
9 apparatus were significantly lower in the PD than in the HD patients. The productivity losses
10
11 in HD patients decreased gradually in the older age groups and were higher than those of PD
12
13 patients were in the same age group (Table 4). Unlike the HD patients, who needed to visit a
14
15 HD centre three times a week, the PD patients could work freely, spent less time in operating
16
17 the dialysis apparatus, and had lower productivity losses. When compared to HD, PD is a
18
19 self-care and timesaving modality, which explains the lower productivity losses. In patients
20
21 with chronic kidney disease stage 5 near ESRD, facing with numerous decisions across the
22
23 trajectory of their illness are needed. Using shared decision-making approach offers a patient-
24
25 centered method to nudge patients facing health-related decisions, including the choice of
26
27 HD, PD, kidney transplantation or hospice care. The OOP costs and productivity losses have
28
29 significant impact on quality of lives and cost of healthcare delivery. Exploring the detailed
30
31 information will provide evidence based, high-quality decision aids and be able to meet
32
33 patients' informational needs. To extend the generalisability of our findings to other national
34
35 health systems, our result demonstrates that PD modality may appear to be more suitable for
36
37 its markedly lower productivity losses for countries with a younger dialysis patient
38
39 population (less than 70 years old), or with a higher value hourly wage or daily wage. The
40
41 population characteristics, summarized in Table 1, serves as a basis for considering extending
42
43 the results to other populations/medical systems. If the baseline characteristics
44
45 (demographics, clinical need) are similar across populations, the generalizability seems more
46
47 convincing.

48
49 The results of this study confirmed HD modality had higher OOP costs and productivity
50
51 losses than PD modality shown in previous studies.^{12 20} This study also found that
52
53
54
55
56
57
58
59
60

1
2
3 productivity losses contributed 15.2% and 16.5% to the total economic burden of HD and
4
5 PD, respectively, which were higher than 12.4% and 9.8% found in the Brazilian study.²⁰

7 This discrepancy may reflect the difference in healthcare system in Taiwan, where medical
8
9 care is mainly financed by National Health Insurance and in Brazil where patients pay out-of-
10
11 pocket for their medical care.
12

14 The results of this study have some limitations. First, the difference in the proportion of
15
16 age groups in HD and PD patients are the major drawback of this study. From the 2016
17
18 Annual Report on Kidney Disease in Taiwan, the mean ages of HD and PD commencement
19
20 in 2014 were 66.7 and 57.3, respectively, which were older than those of HD and PD patients
21
22 in this cross-sectional study (61.0 and 56.2, respectively, Table 1).¹⁵ Due to this difference, it
23
24 was difficult to obtain sampling of these two groups of patients in the similar age range.
25
26 Therefore, we analysed the results by stratifying into four age groups to compare the
27
28 differences. Second, the results of this study should be interpreted cautiously. The sample
29
30 size could not represent the general population of HD and PD patients in Taiwan because the
31
32 sampled patients were also not randomised, although they were sampled from different parts
33
34 of Taiwan. Third, the impaired productivity or reduced effectiveness at work associated with
35
36 HD or PD were not included in this study, so the productivity losses may thus have led to an
37
38 underestimation. Fourth, when designing a question asking patients about their healthcare
39
40 utilization, the optimum recall period is always an issue to tackle. While a shorter recall
41
42 period of healthcare utilization may decrease the likelihood of a recall error, at the same time, it
43
44 also increases the likelihood of missing information. In this study, we chose 12 months as the
45
46 recall period to make sure all out-of-pocket information in the previous year captured in the
47
48 answer and this possibly caused a recall bias.
49
50
51
52
53
54

56 In this study, we present a patient interview survey in Taiwan to analyse the OOP costs
57
58 and productivity losses for HD and PD patients. From a patient's and societal perspective, the
59
60

1
2
3 HD patients have higher OOP costs and productivity losses than the PD patients do in the age
4
5 group less than 70 years old owing to higher productivity losses.
6
7

8 **Contributors:** CHT and YMS: study concept and design. HHC, MJW, BGH, JCT, CCK,
9
10 SPL, and THC: acquisition of data. CCK, CHT and YMS: analysis and interpretation. CHT
11
12 and YMS: drafted the manuscript. HHC, MJW, BGH, JCT, SPL, and THC: critical revision
13
14 of the manuscript for important intellectual content. All authors: approved the final paper.
15
16 CHT and YMS are fully responsible for the paper.
17
18

19
20 **Acknowledgement:** We thank doctors Ming-Kuhn Ruaan, Su-Chen Lin, Jui-Yuan Hung, and
21
22 Wen-Sheng Ko for their assistance in collecting clinical data.
23
24

25 **Funding:** This study was supported by grants from Wan Fang Hospital, Taipei Medical
26
27 University (105TMU-WFH-05).
28
29

30 **Competing interests:** None declared.
31

32 **Data sharing statement:** All relevant data have been included in the paper.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. *Nephrol Dial Transplant* 2008;23(12):3977-82.
2. United States Renal Data System. USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2014.
3. National Health Insurance Administration, Ministry of Health and Welfare. [Available from: https://www.nhi.gov.tw/Content_List.aspx?n=CF2EDC7144006740&topn=D39E2B72B0BDFA15 accessed June 15 2017.
4. Mehrotra R, Chiu YW, Kalantar-Zadeh K, et al. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med* 2011;171(2):110-8.
5. Chang YK, Hsu CC, Hwang SJ, et al. A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. *Medicine (Baltimore)* 2012;91(3):144-51.
6. Karopadi AN, Mason G, Rettore E, et al. The role of economies of scale in the cost of dialysis across the world: a macroeconomic perspective. *Nephrol Dial Transplant* 2014;29(4):885-92.
7. Kao TW, Chang YY, Chen PC, et al. Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan. *Perit Dial Int* 2013;33(6):671-8.
8. Roggeri A, Roggeri DP, Zocchetti C, et al. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. *J Nephrol* 2017;30(2):263-69.
9. Salonen T, Reina T, Oksa H, et al. Cost analysis of renal replacement therapies in Finland. *Am J Kidney Dis* 2003;42(6):1228-38.
10. Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting--a multicentre study. *Nephrol Dial Transplant* 2008;23(6):1982-9.
11. Hornberger J, Hirth RA. Financial implications of choice of dialysis type of the revised Medicare payment system: an economic analysis. *Am J Kidney Dis* 2012;60(2):280-7.
12. Yang F, Lau T, Luo N. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. *Nephrology (Carlton)* 2016;21(8):669-77.
13. Chang YT, Hwang JS, Hung SY, et al. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score. *Sci Rep* 2016;6:30266.

14. Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of renal replacement therapy in Austria. *Nephrol Dial Transplant* 2011;26(9):2988-95.
15. 2016 Annual Report on Kidney Disease in Taiwan. Taipei, Taiwan. 2017.
16. Wu MS, Wu IW, Shih CP, et al. Establishing a platform for battling end-stage renal disease and continuing quality improvement in dialysis therapy in Taiwan-Taiwan Renal Registry Data System (TWRDS). *Acta Nephrologica* 2011;25(3):148-53.
17. Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. *J Am Soc Nephrol* 2012;23(3):533-44.
18. Li PK, Chow KM, Van de Luitgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. *Nat Rev Nephrol* 2017;13(2):90-103.
19. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. *JAMA* 1989;262(20):2879-86.
20. de Abreu MM, Walker DR, Sesso RC, et al. A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil. *Perit Dial Int* 2013;33(3):304-15.
21. Liljas B. How to calculate indirect costs in economic evaluations. *Pharmacoeconomics* 1998;13(1 Pt 1):1-7.
22. Unemployment rate. : National Statistics, R.O.C. (Taiwan). 2016 [Available from: <https://www.stat.gov.tw/point.asp?index=3> accessed December 31 2016].
23. Bruns FJ, Seddon P, Saul M, et al. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. *J Am Soc Nephrol* 1998;9(5):884-90.

Table 1. Patient characteristics of the interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Male gender	156 (50.7)	124 (50.4)	0.96
Age (y)	61.0 [12.7]	56.2 [13.9]	<0.01
<50	68 (22.1)	71 (28.9)	
50-59	79 (25.7)	67 (27.2)	
60-69	76 (24.7)	70 (28.5)	
≥70	85 (27.6)	38 (15.5)	
Comorbidities			
Diabetes mellitus	130 (42.2)	74 (30.1)	<0.01
Hypertension	204 (66.2)	193 (78.5)	<0.01
Cancer	17 (5.5)	7 (2.9)	0.13
Chronic obstructive pulmonary disease	5 (1.6)	2 (0.81)	0.40
Cirrhosis of liver	5 (1.6)	3 (1.2)	0.91
Dementia	3 (1.0)	4 (1.6)	0.50
Cerebrovascular disease	8 (2.6)	6 (2.4)	0.91
Peripheral vascular disease	15 (4.9)	8 (3.25)	0.34
Cardiac dysrhythmia	36 (11.7)	20 (8.1)	0.17
Ischemic heart disease	22 (7.1)	6 (2.4)	0.01
Myocardial infarction	11 (3.6)	8 (3.3)	0.84
Chronic heart failure	13 (4.2)	9 (3.7)	0.74
Cause of end-stage renal disease			
Chronic glomerulonephritis	111 (36.0)	82 (33.3)	0.44
Diabetes mellitus	118 (38.3)	71 (28.9)	0.11
Hypertension	108 (35.1)	52 (21.1)	0.02
Hereditary polycystic kidney disease	10 (3.3)	6 (2.4)	0.83
Chronic tubulointerstitial nephritis	5 (1.6)	7 (2.9)	0.19
Lupus nephritis	4 (1.3)	11 (4.5)	<0.01
Others	51 (16.6)	43 (17.5)	0.21
Marital status			0.18
Singled	45 (14.6)	52 (21.1)	
Married	210 (68.2)	159 (64.6)	
Divorced	25 (8.1)	15 (6.2)	
Widowed	28 (9.1)	20 (8.1)	
Education years			0.09
Below primary school	26 (8.4)	15 (6.1)	
Primary school	77 (25.0)	51 (20.7)	
Junior high school	50 (16.2)	31 (12.6)	

1				
2				
3	Senior high school	88 (28.6)	69 (28.1)	
4	College	59 (19.2)	66 (26.8)	
5	Above college	8 (2.6)	14 (5.7)	
6				
7				
8	Family income (NTD)			0.17
9	<30,000	93 (30.2)	80 (32.5)	
10	30,000-49,999	99 (32.1)	61 (24.8)	
11	50,000-69,999	61 (19.8)	46 (18.7)	
12	70,000-99,999	31 (10.1)	25 (10.1)	
13	100,000-149,999	9 (2.9)	23 (9.4)	
14	150,000-199,999	6 (2.0)	8 (3.3)	
15	≥200,000	9 (2.9)	3 (1.2)	
16				
17				
18				
19				

20 Data were number (%) or mean [standard deviation]. HD: haemodialysis; NTD: New Taiwan Dollar (1 US
 21 Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis.

Table 2. Dialysis related baseline data of interview survey patients.

Variables	HD (n=308)	PD (n=246)	<i>p</i> -value
Duration of dialysis (month)	63 (26-135)	37 (16-63)	<0.001
Systolic blood pressure (mmHg)	141.8 [24.7]	141.0 [23.2]	0.58
Diastolic blood pressure (mmHg)	76.1 [12.6]	82.3 [14.9]	<0.001
Heart rate (beats/min)	77.5 [10.3]	81.8 [15.1]	<0.01
Serum albumin (g/dL)	4.0 [0.4]	3.8 [0.7]	<0.001
Serum potassium (mmol/L)	4.8 [0.8]	4.0 [0.6]	<0.001
Standard Kt/V (HD) or Kt/V (PD)	2.39 [0.32]	1.97 [0.31]	<0.001
Urea reduction ratio	73.9 [6.2]	— —	—
Weekly creatinine clearance (ml/min)	— —	60.1 [12.5]	—
Normalized protein nitrogen appearance	— —	1.0 [0.2]	—
Hemoglobin (g/dL)	10.5 [1.5]	10.1 [1.5]	<0.01
Body mass index	23.7 [4.5]	23.9 [3.9]	0.22

Data were median (interquartile range) or mean [standard deviation]. HD: haemodialysis; PD: peritoneal dialysis.

Table 3. Per patient-month out-of-pocket costs of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	5,922 (12,963)	1,794 (488-4,784)	5,237 (7,571)	2,492 (1,018-5,598)	<0.01
Copayment to outpatient care	103 (377)	0 (0-120)	361 (696)	120 (50-400)	<0.001
Copayment to inpatient care	2,209 (11,093)	0 (0-0)	995 (2,163)	0 (0-1,240)	<0.001
Medicine not covered by NHI	591 (1,832)	0 (0-417)	995 (1,911)	125 (0-1,078)	<0.001
Medical equipment	110 (448)	0 (0-0)	439 (726)	208 (0-675)	<0.001
Chinese medication	27 (175)	0 (0-0)	183 (2,153)	0 (0-0)	0.53
Traditional medicine	38 (257)	0 (0-0)	51 (550)	0 (0-0)	0.35
Nutritional supplements	241 (749)	0 (0-0)	542 (2,398)	0 (0-106)	0.26
Transportation costs	1,028 (1,707)	293 (0-1,495)	191 (229)	143 (16-293)	<0.001
Caregiver costs	1,574 (5,453)	0 (0-0)	1,480 (5,309)	0 (0-0)	0.90
Stratified by age groups					
Age <50 (y)	3,766 (5,785)		2,771 (3,150)		0.32
Age 50-59 (y)	4,902 (14,857)		5,824 (7,484)		<0.001
Age 60-69 (y)	7,337 (14,140)		4,091 (6,072)		0.68
Age ≥70 (y)	7,330 (13,980)		10,922 (12,006)		<0.01
After bootstrap procedures					
Total	5,912 (819)		5,225 (485)		<0.001
Stratified by age groups					
Age <50 (y)	3,787 (686)		2,776 (375)		<0.001
Age 50-59 (y)	4,814 (1,678)		5,827 (870)		<0.001
Age 60-69 (y)	7,270 (1,559)		4,111 (701)		<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Age \geq 70 (y)	7,348 (1,521)	10,932 (1,855)	<0.001
-------------------	---------------	----------------	--------

HD: haemodialysis; IQR: interquartile range; NHI: National health Insurance; NTD, New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

For peer review only

Table 4. Per patient-month productivity losses of the interview survey patients (in NTD).

Variables	HD (n=308)		PD (n=246)		<i>p</i> -value
	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	
Before bootstrap procedures					
Total	14,147 (10,746)	13,936 (6,961-20,921)	11,604 (7,949)	10,576 (5,315-16,764)	<0.01
Time spent operating dialysis apparatus	— —	— —	8,655 (6,785)	7,450 (3,138-12,700)	
Seeking outpatient care from patients	11,307 (8,007)	12,874 (0-17,567)	774 (591)	798 (399-1,008)	<0.001
Seeking outpatient care from caregivers	1,608 (5,793)	0 (0-0)	400 (759)	0 (0-833)	<0.001
Seeking inpatient care from patients	799 (1,683)	0 (0-0)	1,037 (1,482)	0 (0-2,918)	0.01
Seeking inpatient care from caregivers	433 (1,251)	0 (0-0)	739 (1,290)	0 (0-733)	<0.001
Stratified by age groups					
Age <50 (y)	19,419 (5,888)		13,177 (7,000)		<0.001
Age 50-59 (y)	19,276 (10,606)		14,424 (7,579)		<0.01
Age 60-69 (y)	17,253 (7,901)		12,826 (6,789)		<0.001
Age ≥70 (y)	2,386 (6,184)		1,207 (1,621)		<0.01
After bootstrap procedures					
Total	14,150 (626)		11,611 (510)		<0.001
Stratified by age groups					
Age <50 (y)	19,381 (715)		13,289 (840)		<0.001
Age 50-59 (y)	19,272 (1,162)		14,415 (878)		<0.001
Age 60-69 (y)	17,212 (857)		12,823 (802)		<0.001
Age ≥70 (y)	2,403 (645)		1,206 (255)		<0.001

HD: haemodialysis; IQR: interquartile range; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); PD: peritoneal dialysis; SD: standard deviation.

Table 5. Total costs of out-of-pocket costs and productivity losses per patient-month of HD and PD patients after bootstrap analysis (in NTD).

Variables	HD	PD	Difference
(1) Out-of-pocket costs	5,912	5,225	687
Stratified by age groups			
Age <50 (y)	3,787	2,776	1,011
Age 50-59 (y)	4,814	5,827	-1,013
Age 60-69 (y)	7,270	4,111	3,159
Age ≥70 (y)	7,348	10,932	-3,584
(2) Productivity losses	14,150	11,611	2,540
Stratified by age groups			
Age <50 (y)	19,381	13,289	6,093
Age 50-59 (y)	19,272	14,415	4,858
Age 60-69 (y)	17,213	12,823	4,390
Age ≥70 (y)	2,403	1,206	1,197
(3) Total costs			
Model 1 = (1) + (2)	20,062	16,836	3,227
Stratified by age groups			
Age <50 (y)	23,168	16,065	7,103
Age 50-59 (y)	24,086	20,242	3,844
Age 60-69 (y)	24,483	16,934	7,549
Age ≥70 (y)	9,751	12,138	-2,387
Model 2 = (1) + (2) x 20% decrement in wages x (1-0.0382)^a	16,800	14,159	2,641
Model 3 = (1) + (2) x 30% decrement in wages x (1-0.0382)^a	15,439	13,042	2,397
Model 4 = (1) + (2) x 40% decrement in wages x (1-0.0382)^a	14,078	11,925	2,153


HD: haemodialysis; PD: peritoneal dialysis; NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars).

^a Adjusted for mean Taiwan unemployment rate (3.82%) between April 2015 and March 2016.

Figure Legends

Figure 1. Distribution of NHI-financed medical cost ¹⁵, out-of-pocket costs, and productivity losses, in HD and PD modalities, and their differences. NHI: National Health Insurance; NTD: New Taiwan Dollar (1 US Dollar = 30 New Taiwan Dollars); HD: haemodialysis; PD: peritoneal dialysis.

For peer review only



221x150mm (300 x 300 DPI)

Supplementary Online Content

Out-of-pocket costs and productivity losses in haemodialysis and peritoneal dialysis from a patient interview survey in Taiwan

Chao-Hsiun Tang, Hsi-Hsien Chen, Ming-Ju Wu, Bang-Gee Hsu, Jer-Chia Tsai, Chi-Cheng Kuo, Shih-Pi Lin, Tso-Hsiao Chen, Yuh-Mou Sue

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

Table S1. Average monthly/hourly wage rate reported by the Directorate-General of Budget, Accounting, and Statistics, Taiwan.

	Monthly income (NTD)	Hourly income (NTD) ^a
Male^b		
15 - 19 years	18,300	103
20 - 24 years	25,680	145
25 - 29 years	33,210	187
30 - 34 years	36,090	203
35 - 39 years	40,470	228
40 - 44 years	43,590	245
45 - 49 years	45,930	259
50 - 54 years	44,280	249
55 - 59 years	43,980	248
60 - 64 years	44,760	252
65 - 69 years	34,740	196
70 & over	0	0
Female^b		
15 - 19 years	16,590	96
20 - 24 years	24,600	143
25 - 29 years	30,420	176
30 - 34 years	32,520	189
35 - 39 years	34,440	200
40 - 44 years	36,000	209
45 - 49 years	36,930	214
50 - 54 years	35,850	208
55 - 59 years	34,830	202
60 - 64 years	34,440	200
65 - 69 years	23,100	134
70 & over	0	0
Caregivers^b		
	36,510	208

NTD, New Taiwan Dollar, 1 US Dollar = 30 New Taiwan Dollars.

^a Average hourly income = average monthly income / average monthly working hours.

^b Average monthly working hours: male = 177.6 hrs.; female = 172.5 hrs.; caregivers = 175.3 hrs.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1	Out-of-pocket costs and...
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2	Results: There were...
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5	However, from a patient’s as
Objectives	3	State specific objectives, including any prespecified hypotheses	5	We, therefore, conducted
Methods				
Study design	4	Present key elements of study design early in the paper	5	Study design
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5	Ours was a multicentre study ...
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6	<i>Cross-sectional study</i> Sampling
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		Articulate ESRD patients who were...
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed		
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6	We examine the differences in OOP costs...
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6	OOP costs included all expenses related...
Bias	9	Describe any efforts to address potential sources of bias	7	Sensitivity analysis
Study size	10	Explain how the study size was arrived at	6	Sampling

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7	The patient interviews...
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7	Frequencies for categorical...
		(b) Describe any methods used to examine subgroups and interactions	NA	
		(c) Explain how missing data were addressed	NA	<i>Cross-sectional study</i> , face by face interviews, no missing data.
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	7	Finally, as patient characteristics...
		(e) Describe any sensitivity analyses	7	Sensitivity analysis
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7	A total of 308 HD patients and 246 PD patients...
		(b) Give reasons for non-participation at each stage	NA	
		(c) Consider use of a flow diagram	NA	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7, 15-17	Table 1 and table 2
		(b) Indicate number of participants with missing data for each variable of interest	NA	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA	<i>Cross-sectional study</i>
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	8, 18-20	Table 3 and table 4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8, 18-20	Table 3 and table 4
		(b) Report category boundaries when continuous variables were categorized	8, 18-20	Table 3 and table 4
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful	NA	

		time period		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9, 21	Table 5
Discussion				
Key results	18	Summarise key results with reference to study objectives	9	The main results of...
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11	The results of this study have some limitations...
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11	These findings are...
Generalisability	21	Discuss the generalisability (external validity) of the study results	11	To extend the generalisability of...
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12	Funding: This study

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.